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ABSTRACT 
 
 
Examining Financial Stress and Coping among U.S. Cancer Patients and Survivors: Quantitative 
Analyses of Survey Data 
by 
Meredith Doherty  
 
Advisor: Dr. Daniel Gardner 
 
Financial hardship, a growing problem for cancer patients and survivors, is associated 
with increased pain and symptom burden, reduced quality of life and psychological wellbeing, 
poor treatment adherence, and early mortality. Nearly one in three cancer patients reports that 
cancer caused some financial stress or strain. Emerging research has begun to explore the coping 
strategies used by cancer-affected individuals to manage the direct and indirect costs associated 
with cancer and its treatment. This dissertation seeks to answer three research questions: (1) what 
are the measurable characteristics of different cost-coping strategies? (2) what behavioral, 
institutional, and social factors are associated with variations in coping? and (3) to what extent 
do these distinct coping strategies mediate and/or moderate the relationship between material 
financial stress and perceived financial strain?  
To address these research questions, multivariate statistical methods were used to analyze 
existing survey data on the financial concerns from a stratified, random, national sample of 
insured cancer patients and survivors (N = 511). Exploratory factor analysis was used to identify 
the four underlying dimensions of problem-focused cost-coping and delineate working scales for 
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each hypothesized coping strategy: care-altering, lifestyle-altering, self-advocacy and financial 
help-seeking. Stepwise logistic regression was used to model significant predictors of each cost-
coping strategy. Lastly, to explore the possible effectiveness of each cost-coping strategy, linear 
regression-based mediation and moderation modeling using Hayes’ PROCESS analysis was used 
to measure the extent to which each strategy intervened in the  relationship between material 
financial stress and the perceived financial strain.   
Two strategies played meaningful intermediary roles: lifestyle-altering and self-
advocacy. Lifestyle-altering, used more often by women and people of color, partially mediated 
the positive, linear relationship between stress and strain (B = 0.08, p<.05). Self-advocacy 
interacted with stress to buffer its impact on perceived financial strain (B=-0.01, p<.01). 
Findings from this study contribute to the literature on financial stress and strain as social 
determinants of health by proposing a model of financial coping in cancer that may facilitate the 
development of interventions, programs and policies that improve financial wellbeing in people 
affected by cancer by supporting successful coping and targeting the delivery of material and 
psychosocial resources where they are needed most.  
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CHAPTER I. STATEMENT OF THE STUDY ISSUE 
Rationale and Significance 
People diagnosed with cancer are materially and psychologically unprepared to deal with 
the costs of care. They typically encounter unexpected out-of-pocket medical expenses and may 
be limited in their ability to work for periods of time (CancerCare, 2016; Yabroff et al., 2015). 
The combined financial burden of treatment and potential for lost income is a major source of 
stress for people affected by cancer (Altice, Banegas, Tucker-Seeley, & Yabroff, 2017; Azzani, 
Roslani, & Su, 2015). Moreover, a growing number of studies have linked this experience of 
financial hardship to poor health outcomes and early mortality (Ramsey et al., 2016; Zafar & 
Abernethy, 2013).  
Financial hardship in cancer is widespread and growing. Each year almost two million 
American men and women receive a diagnosis of cancer, and there are currently over 15.5 
million cancer survivors in the United States (American Cancer Society, 2016; Siegel, Miller, & 
Ahmedin, 2016). At least one third will experience a degree of financial hardship due to out-of-
pocket medical expenses and wages lost due to disability (Yabroff et al., 2015). For many, 
cancer-related financial hardship persists beyond the acute phase of their illness and throughout 
survivorship (Jagsi et al., 2014). Coping with these expenses affects not only the person with 
cancer, but their family, and the wider community as well.  
The treatment advances of recent decades have improved survival and decreased overall 
mortality from cancer, but have also added significant cost to standard treatment protocols. 
Cancer patients have substantially greater out-of-pocket treatment costs and 2.5 times the risk of 
personal bankruptcy of people with other health conditions (Cohen, Gindi, & Kirzinger, 2012; 
Claxton, Panchal, Whitmore, Damico, Kenward, & Long, 2015; Ramsey et al., 2013). Even after 
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active treatment cancer survivors are more likely to have high personal debt and negative net 
worth, and are less likely to own homes than people without a cancer history (Doroudi, 
Coughlan, Banegas, Han, & Yabroff, 2018).  
In response to rising healthcare costs, many insurance plans have employed cost-sharing 
mechanisms that increasingly shift the burden to patients in the form of co-insurance, co-pays, 
deductibles and monthly premiums (Collins, Rasmussen, Beutel, & Doty, 2015). Cost sharing 
related to prescription medication, outpatient care and hospital stays constitute the greatest 
portion of these expenses, respectively (Zafar & Abernethy, 2013). In a 2016 survey conducted 
by the national organization CancerCare, respondents between the ages of 25-64 reported 
average monthly out-of-pocket expenses of $1,112 for their cancer treatment (CancerCare, 
2016). Similarly, a recent analysis of 2002-2012 Health and Retirement Study data indicated that 
the average annual out-of-pocket cancer treatment costs in a nationally representative sample of 
1,409 traditional Medicare beneficiaries was $8,115 (Narang & Nicholas, 2016). For context, the 
median household income in 2015 was $38,515 for individuals 65 and older (U.S. Census 
Bureau, 2017), suggesting that many individuals may spend over 20% of their household income 
on out-of-pocket cancer costs.  
Individuals and families who spend 10-20% or more of their household income on out-
of-pocket medical expenses are considered underinsured (Collins et al., 2015) . The number of 
underinsured Americans is climbing. According to the 2014 Commonwealth Fund Biennial 
Health Insurance Survey, the number of underinsured Americans nearly doubled from 16 million 
in 2004 to 31 million in 2014. For the underinsured, high out-of-pocket costs can lead to large 
amounts of debt, personal bankruptcy and difficulty adhering to treatment (Collins et al., 2015; 
Dusetzina, Winn, Abel, Huskamp, & Keating, 2014; Kaisaeng, Harpe, & Carroll, 2014). A recent 
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study found that the gains in coverage rates secured by the Patient Protection and Affordable 
Care Act of 2010 did not reduce the number of bankruptcies caused by serious illness and its 
treatment (Himmelstein, Lawless, Thorne, Foohey, & Woolhandler, 2019).  
The excessive cost of care has well-documented health consequences. A growing body of 
evidence has linked cancer-related financial hardship to adverse health and treatment outcomes. 
Strong associations have been documented between cancer patients’ experience of financial 
hardship and reduced quality of life (Arastu et al., 2018; Fenn, 2014; Kale & Carroll, 2016; 
Lathan et al., 2016, 2016; Zafar et al., 2015), increased pain and symptom burden (Chan et al., 
2018; Delgado-Guay et al., 2015; Lathan et al., 2016; Rios & Zautra, 2011), and early mortality 
(Ramsey et al., 2016). Furthermore, patients who experience financial hardship are more likely 
to report treatment delays (Casilla-Lennon et al., 2018; Wharam et al., 2019) and difficulty 
adhering to treatment. Many report delaying or forgoing recommended treatments and cutting 
back on prescribed medications to reduce their out-of-pocket costs (Bestvina et al., 2014). The 
term financial toxicity is now used to refer to the demonstrated impact of financial hardship on 
these health and treatment-related outcomes (Zafar & Abernethy, 2013). Such outcomes are 
distinct from health outcomes associated with low socioeconomic status alone, and have been 
identified across the spectrum of income and insurance status. As such, financial toxicity is 
increasingly cited as a common side effect cancer care, as well as a social determinant of health 
(Tucker-Seeley & Yabroff, 2016). 
Although financial toxicity has been reported by individuals across the socioeconomic 
continuum (Tucker-Seeley & Yabroff, 2016) studies have shown that women, individuals 
identifying as racially/ethnically nonwhite, non-English speakers and those with lower 
educational attainment are more likely to experience cancer-related financial hardship and its 
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attendant health consequences (Knight et al., 2018; Ramsey et at., 2016; Shankaran, Jolly, 
Blough, & Ramsey, 2012).  These studies build upon well-documented racial/ethnic and 
socioeconomic disparities in cancer incidence and mortality (Ward et al., 2004). Financial 
toxicity may represent a downstream social determinant of health and a potential driver of cancer 
health disparities for socially disadvantaged communities.  
The construct of cost-coping describes the strategies used by cancer patients and 
survivors to manage financial stress and balance their personal and household financial needs 
with the costs of treatment (Zullig et al., 2013). Although the literature posits multiple cost-
coping strategies (Head, Harris, Kayser, Martin, & Smith, 2018; Nipp et al., 2016) and has 
implicated cost-coping in the development of negative health effects (Carrera, Kantarjian, & 
Blinder, 2018; Zafar, 2016), in-depth knowledge of the range of strategies used by financially 
stressed households is sparse. There is reason to believe that cost-coping strategies can either 
buffer or exacerbate the impact of financial stress on health and wellbeing. Citing threats to 
public health, oncology providers and researchers have called for evidence-informed strategies to 
prevent financial stress and coping from undermining patient care and outcomes (Tucker-Seeley 
& Yabroff, 2016).  
Social Work Role 
Guided by the ethical principle of promoting social justice, the social work profession is 
commited to eliminating  race- and class-based health disparities and building the financial 
capacity of underserved communities (National Association of Social Workers [NASW], 2017; 
Uehara et al., 2013). In many health care settings social workers are responsible for identifying 
and addressing patients’ financial needs and concerns. Oncology social workers have cited 
financial and insurance difficulties as the foremost barrier to accessing high quality cancer care 
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(Burg et al., 2010) and have called for improved screening and financial resource identification 
tools (Smith, Nicolla, & Zafar, 2014).  
A deeper, more contextual understanding of financial stress and coping can inform the 
development of social work assessment and interventions that promote effective coping and 
financial wellbeing in cancer patients and survivors. A working measure of cost-coping can be 
useful in development of clinical tools that can be used to identify individuals at risk of financial 
stress, strain, and maladaptive coping strategies. Understanding the risk factors associated with 
different coping strategies may aid in the development of targeted community and population 
level interventions that direct material and psychosocial resources where they are needed. This 
study contributes to an emerging literature that posits cancer-related financial hardship as a 
health equity issue which disproportionately impacts women, the poor, and people of color. 
Specific Study Aims 
 This exploratory study seeks to improve our understanding of the problem-focused cost-
coping strategies used by cancer patients and survivors by (1) identifying the measurable 
characteristics of cost-coping and its subdimensions; (2) identifying the behavioral, social and 
health system factors that predict variations in coping; and (3) measuring the extent to which 
different coping  strategies mediate or moderate the relationship between material financial stress 
and the subjective experience of financial strain. In order to address these aims, I conducted an 
analysis of secondary, cross-sectional data from an online survey of cancer patients and survivors 
(n=511) regarding their concerns about finances and health insurance. The overarching goals of 
the study are to produce a formative, working measure of cost-coping, identify modifiable 
factors associated with variations in coping, and measure the extent to which coping strategies 
succeed in buffering the impact of financial stress on wellbeing to develop a preliminary model 
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of financial hardship and cost-coping in cancer patients and survivors. Specifically, the study 
seeks to test the following hypotheses and accomplish the following aims: 
Aim 1 
 Identify, through exploratory factor analysis techniques, measurable characteristics of 
cost-coping and its subdimensions in the survey data. H1: Cost-coping is a measurable latent 
construct that can be measured across multiple subdimensions. 
Aim 2 
 Identify behavioral, social, and health system factors that most strongly predict variations 
in cost-coping. Specifically, stepwise logistic regression is employed to predict cost-coping 
outcomes from behavioral (e.g. patient activation score), health system (e.g. health insurance 
type and associated out-of-pocket medical costs), and social (e.g. gender, race/ethnicity, and 
income). H2: Coping style will vary by behavioral, health system, and social factors such that, 
upon examination of multiple indicators, distinct typologies and modifiable factors will emerge.  
Aim 3 
 Measure, using Hayes’ PROCESS method of regression-based mediation and moderation 
analysis, the extent to which different cost-coping strategies mediate or moderate the relationship 
between material financial stress (i.e. difficulty paying bills due to cancer treatment) and 
financial strain (i.e. psychological distress attributed to finances). H3: Each cost-coping strategy 
will have a distinct and measurable impact on the relationship between financial stress and 
financial strain. 
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CHAPTER II. REVIEW OF THE LITERATURE 
Financial Stress and Strain 
 One of the challenges of conducting research on financial hardship in cancer is the lack 
of consistency in naming and defining the phenomenon. Financial hardship encompasses both 
the subjective and objective experiences of cancer patients and survivors when they encounter 
difficulties balancing their household financial responsibilities with the direct and indirect costs 
associated with their cancer diagnosis. One way of understanding the construct divides it into 
two dimensions: financial stress and financial strain. Financial stress represents objective, 
measurable financial demands, and financial strain represents one’s subjective perception of 
difficulty or distress related to managing those demands (Francoeur, 2005; Sharp, Carsin, & 
Timmons, 2013). Both financial stress and strain have been associated with adverse 
psychological outcomes including increased distress, depression, and anxiety in cancer patients 
and survivors (Ell, et al., 2008; Sharp, et al., 2013). Individuals and groups vary in the degree to 
which financial stress leads to subjective strain. Although financial stress and strain tend to be 
significantly correlated on average, the pattern and strength of the relationship depends on 
mediating and moderating factors, including a patient’s ability to rally personal and social 
resources in order to cope with stress (Francoeur, 2005).  
Cost-Coping Strategies 
In their conceptual framework of financial hardship in cancer, Altice and colleagues 
(2017) added a third feature to the stress and strain model: coping behaviors. Their model 
proposed three distinct but overlapping dimensions: (1) material conditions, (2) psychological 
responses, and (3) coping behaviors. Their review of the empirical literature identified patterns in 
measuring these three dimensions. The material conditions typically measured in research on 
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financial hardship include out-of-pocket expenses, missed work, lost income, medical debt and 
bankruptcy. Psychological responses are often measured in terms of subjective distress about 
managing household finances after or during cancer treatment. Coping behaviors they identified 
in the literature related to care- and lifestyle-altering behaviors like delaying or forgoing medical 
care, reducing medications to save money, and cutting back on essential and non-essential 
household spending.  
 Despite the abundant and growing body of literature on financial hardship, coping 
strategies have been relatively understudied (Carrera et al., 2018). Coping falls broadly into two 
types: (1) person-oriented/emotion focused and (2) task/problem focused (Head, et al., 2018; 
Lazarus & Folkman, 1984). In qualitative interviews with financially-burdened cancer patients, 
Head and colleagues (2018) identified a number of emotion and problem focused coping 
strategies. In their study they found people were engaged in emotion focused cost-coping 
strategies like using personal strengths, accessing social support, expressing emotion and 
engaging in self-care. They also described problem focused strategies like going into debt, 
accessing financial assistance, making lifestyle changes, changing treatment protocol, being 
proactive and negotiating with insurance.  
Care-altering and lifestyle-altering are two cost-coping strategies that have received the 
most scholarly attention to date (Bestvina et al., 2014; Huntington et al., 2015; Irwin et al., 2014; 
Jagsi et al., 2014; Kent et al., 2013; Lee & Khan, 2016; Lee & Salloum, 2016; Nipp et al., 2016; 
Zafar, Chino, Ubel, Rushing, & Samsa, 2015; Zullig et al., 2013). As stated previously, care-
altering describes how some cancer patients and survivors cope with the cost of their care by 
delaying or forgoing aspects of medical treatment. Lifestyle-altering refers to coping with the 
costs of care by altering spending and borrowing habits (Nipp et al., 2016).   
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Care-altering, also referred to as cost-related nonadherence (CRN), has been associated 
with adverse health consequences in cancer and other illnesses (Hershman et al., 2011; Osterberg 
& Blaschke, 2005). Although the exact estimates are unknown, two large population-based 
studies using data from the National Health Interview Survey from 2003-2006 (Weaver, 
Rowland, Bellizzi, & Aziz, 2010) and 2010 (Kent et al., 2013) concurred that 10-20 percent of 
cancer patients and survivors had delayed or declined necessary medical care in the last 12 
months due to cost.  
The only reliability-tested measure of care-altering is a measure of cost-related 
medication nonadherence. Respondents are asked if in the last six months they have ever skipped 
a dose of medication, took a smaller dose, or delayed refilling, and how many times in the last 12 
months they did not fill a prescription (Pierre-Jacques et al., 2008). Many care-altering and CRN 
studies adapted this instrument to measure other kinds of treatment nonadherence, like delaying 
or forgoing medical appointments and testing.  
 The two primary drivers of care-altering that have been identified in the empirical 
literature are financial hardship and high out-of-pocket medical costs. The risk of engaging in 
cost-related medication nonadherence has been positively correlated with rising prescription co-
payments (Dusetzina et al., 2014; Kaisaeng et al., 2014; Neugut et al., 2011; Streeter, 
Schwartzberg, Husain, & Johnsrud, 2011) and self-reported financial stress and strain (Kent et 
al., 2013; Markman & Luce, 2010; Zafar et al., 2013; Zullig et al., 2013). Other factors that have 
been empirically linked to care-altering behavior in past studies are age, race/ethnicity and 
gender. Analyzing a nationally representative sample of cancer patients and survivors, Lee and 
colleagues found that younger patients, women, African American and Hispanic individuals 
were more likely to cite treatment costs as a barrier to adherence (Lee & Khan, 2016; Lee & 
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Salloum, 2016). These demographic disparities by age, gender and race are persistent and have 
also been found in smaller, less heterogeneous study samples (de Souza, Kung, O’Connor, & 
Yap, 2017; Martin, Shreffler, Schoster, & Callahan, 2012; Zafar et al., 2013).  
 People respond to financial hardship and out-of-pocket costs differently. Under the same 
financial circumstances, only some patients respond by altering care and reducing adherence to 
treatment and medication (Briesacher, Gurwitz, & Soumerai, 2007). Piette et al. (2006) proposed 
a conceptual model of factors influencing care-altering behavior in people with chronic illness. 
The model proposes that there are, in addition to primary financial pressures, interactional 
factors related to clinician, patient, health system and medication characteristics that increase 
one’s risk of care-altering (Piette, Heisler, Horne, & Alexander, 2006). Patient-physician trust 
(Piette, Heisler, Krein, & Kerr, 2005) and patient health beliefs (Piette, Beard, Rosland, & 
McHorney, 2011) have been identified as possible mediators of the relationship between 
financial hardship and care-altering. Efforts to identify other modifiable factors associated with 
care-altering behavior is ongoing.  
  Like care-altering behaviors, lifestyle-altering strategies range in severity. Some cope 
proactively by simply cutting back on leisure spending, while other people are driven to cut back 
on basics like food and clothing or to depleting assets, borrowing money and filing for 
bankruptcy (Altice et al., 2017). As a singular concept, lifestyle-altering has been relatively 
understudied and efforts to operationalize and measure it are incomplete. However, aspects of 
lifestyle-altering such as changing spending habits, borrowing money, and filing for bankruptcy 
have been well-documented (Altice et al., 2017; Head et al., 2018; Nipp et al., 2016). Nipp and 
colleagues (2016) delineated lifestyle-altering cost-coping with the following survey items 
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(adapted from Schrag et al., 2009): reduced spending on basics and on leisure activities, 
borrowed money, used savings, family worked more, and/or sold possessions.  
Many studies of lifestyle-altering have used small, convenience samples which make it 
difficult to estimate its prevalence. However, the accumulated evidence suggests that many 
cancer patients and survivors alter their lifestyle, spending and borrowing habits to accommodate 
the costs of treatment (Jagsi et al., 2014; Markman & Luce, 2010; Meneses, Azuero, Hassey, 
McNees, & Pisu, 2012; Shankaran et al., 2012; Zafar et al., 2013; Zafar et al., 2015). For 
example, in studies of cancer patients who had contacted a financial assistance program, 68-78 
percent cut back on leisure activities, 46-57 percent reduced spending on basics like food and 
clothing, and  46 – 50 percent used savings to pay for treatment (Nipp et al., 2016; Zafar et al., 
2013). Patients commonly borrow from friends, family and banks to cover expenses, such that 
nearly 3 percent of American cancer survivors file for bankruptcy within two years of diagnosis 
(Meneses et al., 2012; Nipp et al., 2016; Zafar et al., 2013).  
In addition to the potential for lifestyle-altering to affect quality of life (Meneses et al., 
2012), some of these coping strategies have been shown to impact physical health outcomes. A 
2016 study conducted by Ramsey and colleagues (2016) revealed that cancer survivors who filed 
for bankruptcy died earlier than propensity score matched counterparts who had not filed for 
bankruptcy. These findings suggest that some forms of care- and lifestyle-altering coping are 
potentially dangerous, and may carry higher risks for health and wellbeing than other cost-coping 
strategies.  
Predictors of Financial Stress and Variations in Coping 
Financial hardship has been reported across demographic populations but is known to 
disproportionately impact younger patients, women, and African American and Hispanic 
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individuals (Ramsey et al., 2016; Shankaran et al., 2012). These associations persist across 
studies despite some differences in the definition and measurement of financial hardship (Altice 
et al., 2017).   
Nipp and colleagues (2016) conducted a small study (n=174) using a cross-sectional 
survey to disentangle care-altering and lifestyle-altering strategies and identify predictors of each 
coping style among adult cancer patients receiving financial assistance program. To predict each 
cost-coping outcome, they examined the following patient characteristics: age, marital status, 
race, income, education, chemotherapy duration, cancer site, and presence of metastatic disease. 
They found that both care- and lifestyle-altering were associated with younger age (< 65), lower 
income, higher education, non-breast cancer diagnosis and non-metastatic disease. Among these 
respondents, those at risk for care-altering, rather than lifestyle-altering, were more likely to be 
younger (<65) and have lower incomes (< $20,000/year). Unlike other studies, race/ethnicity was 
not significantly associated with financial hardship and cost-coping.  
The study by Nipp et al. (2016) surveyed a small sample that overrepresented individuals 
with breast cancer, and had a low response rate, so findings may not accurately reflect the 
general population of cancer patients and survivors. When designing the measure and developing 
statistical models, the researchers did not include behavioral factors that might have provided 
psychological insight into what motivates people to cope with financial stress in different ways. 
Similarly, positive coping like self-advocacy and help-seeking were not examined. Further 
research is needed to develop distinct, comprehensive typologies of cost-coping which can be 
used to identify patients who may be at risk of engaging in riskier coping strategies like care-
altering. 
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The extent to which past studies of financial hardship and cost-coping were explicitly 
informed by social or behavioral theory is unknown. There is a clear conceptual connection to 
the theories, models and frameworks that form the social determinants of health research 
paradigm. For example Pearlin’s Stress Process Model (Pearlin, 1989; Pearlin, Menaghan, 
Lieberman, & Mullan, 1981), described in the next section, provides a rationale and framework 
for examining the mediating effects of coping on the relationship between financial stress and 
strain. However, Pearlin’s model has not been applied to an empirical examination of cost-
coping in cancer patients and survivors. The following section presents how this theoretical 
framework will guide each of the research aims.  
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CHAPTER III. CONCEPTUAL FRAMEWORK  
 This study is conceptually organized by Pearlin’s Stress Process Model, a sociological 
adaptation of stress and coping theory. The Stress Process Model invokes social structural 
relationships to illustrate the processes of toxic stress development that are thought to underlie 
the disparities in health attributed to differences in race, gender, and socioeconomic status.  
Expanding upon Selye’s original conceptualization of stress (Selye, 1956), the Stress 
Process has three elements: (1) stressors, (2) stress mediators, and (3) stress outcomes (Pearlin et 
al., 1981). Stressors can be thought of as threatening or burdensome experiences that an 
individual must respond to, stress mediators are internal and external resources that individuals 
leverage to manage stressful experiences (e.g. coping). Stress outcomes are the effects of 
stressful experiences, such as distress and other health effects (Pearlin, 1989). In this model, both 
stressors and stress mediators are determined by psychosocial and environmental factors like 
socioeconomic status and social role.  
 Early stress and coping theory emphasized internal, psychological processes (Lazarus, 
1993). But has since grown to include social and relational factors. Link and Phelan (1995) 
proposed a link between social stress and illness, proposing that socioeconomic status functions 
as a fundamental cause of health disparities that cannot be fully accounted for by individual 
behavior or lifestyle factors. Like earlier theories of stress, the sociological perspectives 
acknowledge that stress has a direct impact on physical and mental health, but adds that social 
roles and socioeconomic status determine the type and magnitude of stress that one is exposed to. 
This differential exposure to stress is thought to be responsible for health outcomes that vary by 
race, gender, marital status and income (Thoits, 2010). Stressors can be acute, life events or they 
can be chronic conditions that allow stress to proliferate across the life course and across 
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generations (Aneshensel, 1992; Thoits, 2010). In a persistently inequitable society, race, class 
and gender can be considered primary sources of stress (Dohrenwend & Dohrenwend, 1970). 
  People vary in their vulnerability and response to stress. This may be attributed to their 
ability to cope with stressful experiences, since coping has been shown to reduce the impact of 
stressors (Thoits, 2010). Coping, when personal and social resources are rallied to manage a 
stressful experience, is thought to mediate the impact of stress on physical and mental health 
outcomes. Coping strategies are characterized as emotion- or problem-focused, and have 
differing degrees of success in proactively managing stress (Lazarus, 1993). Emotion-focused 
strategies focus on managing thoughts, perceptions and feelings to reduce stress, while problem-
focused coping attempts to reduce stress by changing the external circumstances. Not all coping 
strategies produce positive outcomes. Some strategies exacerbate primary stressors, causing 
further problems and producing secondary and tertiary compounding stressors (Pearlin, 1989; 
Pearlin & Bierman, 2013). Coping is, as well, a socially-situated phenomenon that varies by 
one’s access to psychosocial and material resources (Thoits, 2006).  
  Conceptually and methodologically, coping can function as either a mediator or 
moderator of the impact of stressors on stress outcomes (Frese, 1986). Coping acts as a mediator 
when it links stressors to stress outcomes in a causal pathway. It should therefore be significantly 
correlated with both the antecedent stressor and the stress outcome. When coping acts as a 
moderator, it interacts with the antecedent stressor to either increase or decrease the stressor’s 
effect on the outcome. This study applies the Stress Process Model to develop a model of 
financial hardship and cost-coping in cancer patients and survivors (see Figure 1), and tests 
coping as a mediator (see Figure 2) and moderator (see Figure 3) of the stress process. Financial 
stress acts as the stressor and financial strain acts as the stress outcome.  
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Figure 1. Stress process model adapted for financial stress and cost-coping. Adapted from 
Understanding health disparities: The promise of the stress process model (p. 5), by R.J. Turner. 
In W.R. Avison, C.S. Aneshensel, S. Schieman, & B. Wheaton (Eds.). Advances in the 
conceptualization of the stress process: Essays in honor of Leonard I. Pearlin, 2009, New York, 
NY, Springer Science and Business Media.  
 
 
Figure 2. Cost-coping as a mediator in the stress process 
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Figure 3. Cost-coping as a moderator in the stress process  
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CHAPTER IV. METHODOLOGY 
Overview 
This exploratory study examined the cost-coping strategies of adults living with cancer by 
conducting secondary analysis of cross-sectional survey data on the financial concerns of 511 
cancer patients and survivors, described further below (CancerCare, 2016) . The study was 
designed to achieve three specific aims:  
Aim 1: Apply factor analysis techniques to survey data to develop a preliminary measure of cost-
coping and its subdimensions. 
Aim 2: Use step-wise logistic regression to model the significant social, behavioral and health 
system factors that most strongly predict variation in cost-coping. 
Aim 3: Measure the extent to which each cost-coping strategy mediates and/or moderates the 
relationship between financial stress and strain. 
3a) Regression-based simple mediation model to measure extent to which each coping strategy 
explains the impact of financial stress on the experience of financial strain.  
3b) Regression-based moderation models to measure the extent to which each strategy either 
buffers or amplifies the impact of financial stress on the experience of financial strain.   
Design and Sample 
Cross-sectional survey data for this dissertation have been provided by CancerCare, a 
non-profit psychosocial support organization for people affected by cancer (see Appendix 2 for 
data use agreement). Between July and December 2015 CancerCare conducted the “Cancer 
Patient Access and Engagement Study”, a series of six online cross-sectional surveys on the 
experiences of cancer patients and survivors across the continuum of care. The surveys were 
developed by CancerCare staff in collaboration with leaders in oncology research to capture and 
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describe the unmet needs of U.S. cancer patients and survivors across six areas of care: (1) 
understanding the diagnosis of cancer; (2) treatment planning; (3) communication with the care 
team; (4) financial and insurance issues; (5) symptoms, side effects and quality of life; (6) 
survivorship. The surveys were pilot-tested with a sample of CancerCare participants for 
feasibility and then administered online to a sample drawn from national market research panels.  
To participate, respondents had to: (1) be 25 years of age or older, (2) have ever been 
diagnosed with cancer by a medical professional, and (3) have health insurance. Respondents 
were drawn from national consumer panels used in market research and contacted by email to 
participate in an online survey about their experiences accessing and engaging in health care. 
Approximately 3,000 email invitations were sent out per survey. Online filters were used to 
select a purposive, stratified sample of cancer patients and survivors to represent population 
distributions by U.S. geographic region and cancer type. To match U.S. national demographic 
data, approximately 25% of respondents were selected to represent each geographic region 
(Northeast, Southeast, Western US, and Midwest). Fifty percent of participants were drawn to 
represent the major cancer-types (breast, colorectal, lung, and prostate cancer) and the remaining 
half represented all other cancers excluding non-melanoma skin cancer (CancerCare, 2016). 
This dissertation analyzed data from one of the six surveys from the original study, the 
survey of patients’ financial and insurance concerns which was completed 511 cancer patients 
and survivors. If 3,000 invitations were sent then 17% of those contacted were both eligible to 
participate and completed the survey (see Table 2 for sample characteristics). As a secondary 
data analysis, this dissertation posed unique research questions that were not asked in the original 
descriptive study and tested hypotheses for financial hardship and coping that were not part of 
the original study.  Sample characteristics can be found in Table 2.  
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Measures 
The survey includes 51 items related to the financial impact of cancer and coping with 
the cost of care. Some of the items are unique to this study and others were drawn from federal 
health service research surveys like the National Health Interview Survey and the Medical 
Expenditures Panel Survey (Yabroff et al., 2012). Only one measure in the survey has been 
psychometrically evaluated in past studies, the patient activation measure (PAM-10), a validated 
and reliable measure designed to assess individuals’ ‘self-concept as manager of their own health 
needs’ where higher scores indicate higher activation (=0.82) (Hibbard & Gilburt, 2014, p. 8).  
Cost-coping 
To estimate cost-coping, 32 survey items were selected from the 51 items that constitute 
the original survey. The principal investigator selected these items following a comprehensive 
review of the scholarly literature on financial stress and coping in cancer. The items selected are 
similar to the unvalidated measures used in past studies Jagsi et al., 2014; Nipp et al., 2016; 
Zullig et al., 2013).   
“How often (never, rarely, sometimes, often or always) did/do you do each of the following in 
order to reduce your expenses related to your cancer treatment… (1) postpone or skip medical 
appointments; (2) postpone or skip follow up testing; (3) postpone or skip bloodwork; (4) delay 
or skip complementary treatment; (5) postpone or skip psychological support; (6) skip dosage of 
prescribed drugs; (7) cut pills in half; (8) apply for copay assistance for medication; (9) discuss 
changing treatments to one that costs less; (10) choose a lower cost medication than what the 
doctor recommended; (11) apply for financial assistance for non-medical expenses; (12) order 
medication from outside US online; (13) apply for financial assistance from my doctor; (14) 
estimate cost before agreeing to treatment; (15) appeal a denial of benefit from you insurance 
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company; (16) find out cost before filling a prescription for side effects/symptoms; (17) estimate 
cost before going to emergency room; (18) review the explanation of benefits from insurance 
company; (19) ask insurance company for help understanding coverage; (20) find out cost of lab 
test or scans before agreeing to treatment; (21) considered changing to a different doctor because 
of cost; (22) considered a non-traditional treatment that costs less.”  
“Which of the following have you experienced as a result of bills related to your cancer 
treatment (yes or no)…(23) I declared bankruptcy; (24) I borrowed money from a bank or credit 
union; (25) I cut back on non-essential items; (26) I borrowed money from family/friends; (27) I 
moved to a less expensive home; (28) I missed rent/mortgage payments; (29) I cut back on 
groceries, transportation, clothing, tuition; (30) I missed paying bills like heat, electricity, phone; 
(31) I asked for financial help from a church or community organization; (32) I applied for 
financial assistance from a patient support organization.”  
Domain 1: Demographics 
Current age.  Age was measured as a categorical variable with six categories, which 
were collapsed prior to analysis into the following two categories: (1) 25-64; (2) 65 or older. The 
cutoff threshold was selected because studies have shown significant differences in exposure to 
financial hardship by age, in which individuals under 65 have greater risk of financial hardship 
(Knight et al., 2018).   
Race/Ethnicity.  Race and ethnicity were measured as a mutually exclusive categorical 
variable with the following seven categories: (1) African American; (2) Asian; (3) Hispanic; (4) 
Pacific Islander; (5) White (not Hispanic); (6) Multi-racial; (7) other.  
Gender.  Gender was measured as a categorical variable with two categories: (1) female; 
(2) male.  
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Education.  Education was measured as a categorical variable with seven categories. In 
order to simplify data and improve interpretability of findings, these categories were collapsed 
into two categories: (1) high school diploma or less; (2) some college or more.  
Income.  Income was measured as a categorical response to the following prompt, “What 
was your total 2014 household income before taxes?” Response options are: (1) less than 
$25,000; (2) $25,000 – $34,999; (3) $35,000 – $49,999; (4) $50,000 - $74,999; (5) $75,000 - 
$99,999; (6) $100,000 - $149,999; (7) $150,000 or more; (8) Prefer not to answer. Only the first 
seven responses were used in analyses. To improve the interpretability of analyses the income 
variable was transformed to reflect 2015 Federal Poverty Guidelines for a family of four (U.S. 
Department of Health and Human Services, 2015) so that the final variable contained four 
categorical responses: (1) 150%FPL; (2) 150%-300% FPL; (3) 300%FPL – 600% FPL; (4) 
600% FPL.  
Domain 2: Behavioral 
Patient activation was measured using the 10-item Patient Activation Measure (PAM),  a 
validated measure designed to assess individuals’ ‘self-concept as manager of their own health 
needs’ (Hibbard & Gilburt, 2014, p. 8). The scale contains items related to health beliefs, 
knowledge, skills and confidence. Higher scores indicate greater activation and can be coded and 
analyzed as either continuous (scale of 0-100) or ordinal variables (1-4). See Table 2 for 
frequency distribution of demographic variables.  
Domain 3: Health Status 
Cancer type.  Cancer type was measured with a categorical response to the following 
prompt, “what type of cancer were you most recently diagnosed with?” Response options 
included: (1) bladder; (2) brain; (3) breast (early stage); (4) breast (metastatic); (5) colon or 
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rectal; (6) endometrial/cervical/ovarian; (7) head/neck; (8) kidney; (9) leukemia; (10) liver; (11) 
lung; (l2) lymphoma; (13) melanoma; (14) myeloma; (15) pancreatic; (16) prostate; (17) 
stomach; (18) thyroid; or (19) other.  
Time since diagnosis.  Time since diagnosis was measured with a categorical response to 
the following prompt, “how long ago were you first diagnosed with cancer?” Response options 
include: (1) within the last 12 months; (2) between 13 months and 2 years ago; (3) between 2 
years and years ago; (4) more than 4 years ago.  
Treatment status.  Treatment status was measured with a categorical response to the 
following prompt, “What is your current cancer status?” Response options include: (1) in active 
treatment; (2) completed treatment and on maintenance; (3) completed treatment and not on 
maintenance.  
Work reduction.  Employment changes related to cancer and its treatment were 
measured with a categorical response to the following prompt, “What was your employment 
status while you were being treated for cancer?” Response options included: (1) I continued 
working full time; (2) I continued working part-time; (3) I switched from working full time to 
part time; (4) I stopped working; (5) Does not apply, I was not working before receiving 
treatment. For analyses, this item was transformed into a binary variable where categories 3 and 
4 were collapsed to represent work hour reduction during treatment (yes/no).  See Table 2 for 
frequency distribution of health status variables.  
Domain 4: Health System Factors 
Insurance type.  Insurance type was measured as a categorical, but not mutually 
exclusive, response to the following prompt, “what type of health insurance do you have? Please 
select all that apply.” Response options included: 1) commercial/private insurance through and 
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employer, 2) private insurance via Healthcare.gov (the insurance exchange), 3) 
Medicare/Medicaid, 4) private Medigap, 5) Tricare/Champus.  
Estimated monthly out-of-pocket costs.  Monthly out-of-pocket treatment costs were 
measured using ordinal responses to the following prompt, “Thinking about the time when you 
were getting cancer treatment, on average, how much did you spend (less than $100, $101-$250, 
$251-$500, more than $500, don’t know) out of pocket each month on the following? Your best 
estimate will do:” (1) co-payments and deductibles for drugs, doctor visits and tests; (2) non-
prescription/OTC medications; (3) services to help with symptoms and side effects like 
acupuncture or massage; (4) transportation to and from clinic visits, babysitting; (5) special 
clothing, wigs, etc. Responses to the five items were averaged and scored as a single variable 
ranging from 0-20, where higher scores represent higher estimated monthly out-of-pocket costs.  
Difficulty anticipating out-of-pocket treatment costs.  Difficulty anticipating treatment 
costs, a measure of price transparency, was measured using responses to the following prompt, “ 
How difficulty or easy was it for you to determine the out-of-pocket cost of treatments before 
you incurred the expense?” Ordinal response options were: (1) very difficult; (2) somewhat 
difficult; (3) neither difficulty nor easy; (4) somewhat easy; (5) very easy. For analyses, this item 
was transformed. Categories 1 and 2 were collapsed and a binary variable was created to 
represent those who found out-of-pocket treatment costs to be somewhat to very difficulty to 
anticipate (yes/no).  
Ease of understanding insurance coverage.  Understandability of insurance was 
measured using reponses to the prompt, “how difficulty or easy is it for you to understand what 
your insurance covers for your care” and treated as a continuous variable ranging from 1(very 
difficult) to 5 (very easy). See Table 2 for frequency distribution of health system factors. 
 
 
25 
 
Domain 5: Financial Hardship 
Financial stress.  Financial stress was measured using a single item, “To what degree has 
your cancer treatment caused you financial hardship (i.e. difficulty paying your bills)?” Response 
options included: (1) none; (2) a little; (3) some; (4) a lot; or (5) an extreme amount. For analyses 
this ordinal variable was treated as a continuous variable where higher scores indicated greater 
financial stress.  
Financial strain.  Financial strain, a measure of psychological distress attributed to 
financial hardship, was measured using a single item, an ordinal measure of the degree of 
psychological distress attributed to financial hardship. Respondents were asked, “Thinking about 
a time when you were getting cancer treatment, how distressed (e.g. anxious, extremely upset) 
were you from thinking about your finances? Response options included: (1) not at all distressed; 
(2) a little distressed; (3) somewhat distressed; (4) very distressed or (5) extremely distressed. 
For analyses this ordinal variable was treated as a continuous variable where higher scores 
indicated greater strain.   
Analytic Strategy 
 The following analyses were conducted by the Principal Investigator using StataIC 
(version 15.1): 
Aim 1  
Exploratory factor analysis was conducted to identify the underlying dimensions of cost-
coping among the 32 cost-coping items. The items were first tested for factorability using 
Bartlett’s test of sphericity and Kaiser Meyer-Olkin test (Tabachnick, Fidell, & Ullman, 2007).  
Then, item distributions were tested for normality, which determined the appropriate extraction 
method to use with the data. Because distributions were non-normal and some items were binary, 
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Principle Axis Factor analysis (PAF) was used (Costello & Osborne, 2005). PAF is a common 
method of exploratory factor analysis that measures correlations across multiple items to identify 
underlying “factors.” Factors are highly correlated clusters of survey items which represent 
underlying theoretical concepts or dimensions of a larger theoretical construct. Varimax rotation 
was then used to minimize cross-loading of variables onto multiple factors, a rotation technique 
that can be used to produce more distinct factors or dimensions (Tabachnick, Fidell & Ullman, 
2007).   
Aim 2 
Analyses conducted in Aim 1 produced working measures of four distinct cost-coping 
strategies. These measures were used as outcome variables in Aim 2 to predict variation in cost-
coping from social, behavioral and health system factors using logistic regression. Predictors for 
each cost-coping strategy were grouped into five domains for the initial phase of model building: 
(1) demographics (i.e. age, education, income, race/ethnicity, gender); (2) behavioral 
characteristics (i.e. patient activation score); (3) health status (i.e. cancer type, time since cancer 
diagnosis, treatment status, and work reduction due to illness); (4) health system features (i.e. 
insurance type, difficulty anticipating out-of-pocket treatment cost, ease of understanding 
insurance coverage, average monthly out-of-pocket costs); and (5) financial stress (i.e. cancer-
related difficulty paying bills). Logistic regression was determined to be most readily 
interpretable statistical method for these data, so each outcome variable (i.e. care-altering, 
lifestyle-altering, self-advocacy and financial help-seeking) was transformed into a binary 
variable. Table 1 below presents a frequency table of the transformed binary outcome variables 
used in Aim 2.  
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A model predicting each coping strategy (care-altering, lifestyle-altering and self-
advocacy) was created for each of the five variable domains listed above. First, each independent 
variable in the domain was tested in unadjusted models predicting each cost-coping outcome 
using logistic regression (See Table 4 for independent predictor models). Those found to be 
marginally significant (p < .05) were included in the domain model. Significant predictors in 
each domain were retained and tested in adjusted models predicting care-altering, lifestyle-
altering and self-advocacy coping styles. Predictors that maintained significance in adjusted 
models (p < .05) were included in the final predictive models of each cost-coping strategy.  
For the purpose of conducting regression analyses, independent categorical variables with 
multiple response options were either collapsed into two theoretically meaningful categories 
(e.g., age was collapsed into two groups: 64 and under; 65 and over; education was collapsed 
into two groups: high school education or less and some college or more) or transformed into 
dummy variables where each categorical response was analyzed in the model as a binary variable 
(e.g. cancer type, time since diagnosis and treatment status). Other ordinal variables were treated 
as continuous because they could more easily be understood in terms of magnitude and behaved 
as normally distributed variables. The two variables treated this way were financial stress (M = 
2.43; SD = 1.28) and monthly out-of-pocket treatment costs (M = 7.31; SD = 4.84).  
 The following analyses were conducted by the Principal Invesigator using SPSS Statistics 
(version 25): 
Aim 3 
In accordance with the Stress Process Model which suggests that coping can mediate or 
moderate the relationship between stressors and stress outcomes, each coping variable was tested 
in both possible roles. First, financial stress, strain and the cost-coping strategies were first tested 
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for normality and transformed to meet assumptions of regression-based mediation and 
moderation modeling. Then, in three separate analyses, Hayes’ PROCESS method of simple 
mediation modeling (Hayes, 2012) was used to measure the mediated (direct and indirect) effect 
of care-altering, lifestyle-altering and self-advocacy on the relationship between financial stress 
and strain. To identify possible interaction effects between coping and financial stress in 
predicting financial strain, the PROCESS method of simple moderation modeling was then used 
on all three coping strategies to test for the significance and magnitude of each as conditional 
variables (Hayes, 2012).  
Permission and Human Subjects Review  
I acquired written permission from CancerCare to use data from their Cancer Patient 
Access and Engagement Study for my dissertation, as well as any presentations or publications 
emanating from it (See Appendix 2).  
Ethical Considerations 
Because survey data were de-identified prior to analysis, CUNY Hunter College’s 
Human Research Protection Program determined this study to be exempt from Institutional 
Review Board review. The use of de-identified, existing data for the current study constitutes 
minimal risk to participants. Procedures for informed consent were conducted by the researchers 
responsible for data collection and respondents permitted CancerCare to use their de-identified 
responses for the purposes of ongoing research as part of the informed consent process in the 
original study. The de-identified data were stored in the Principal Investigator’s password 
protected computer and all statistical analyses conducted on that computer at Silberman School 
of Social Work, CUNY Graduate Center, or the PI’s home. Potential benefit to society was 
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assumed to be much greater than the minimal risk associated with the use of this data for the 
proposed study.  
Table 1 
Cost-coping Binary Outcome Variables  
Survey Item Yes-1 No-0 
How often (never, did/do you do each of the following in order to 
reduce your expenses related to your cancer treatment: 
Rarely/ 
Sometimes/Often 
Always 
Never  
Care-altering: (1) postpone or skip medical appointments; (2) 
postpone or skip follow up testing; (3) postpone or skip 
bloodwork; (4) postpone or skip filling a prescription; (5) delay or 
skip complementary treatment; (6) postpone or skip psychological 
support; (7) skip dosage of prescribed drugs; (8) cut pills in half; 
(9) choose a lower cost medication; (10) order medication from 
outside US 
409  101 
Self-advocacy: (1) estimate cost before going to ER; (2) estimate 
cost before agreeing to treatment; (3) appeal a denial of benefit 
from you insurance company; (4) estimate cost before filling a 
prescription; (5) find out cost before filling a prescription for side 
effects/symptoms; (6) review the explanation of benefits from 
insurance company; (7) ask insurance company for help 
understanding coverage; (8) find out cost of lab test or scans 
before agreeing to testing  
428 82 
Financial help-seeking: (1) applied for co-payment assistance; 
(2) applied for financial assistance for non-medical expenses; and 
(3) applied for financial assistance through provider. 
292 218 
Which of the following have you experienced as a result of bills 
related to your cancer treatment: 
  
Lifestyle-altering: (1) I borrowed money from family/friends; (2) 
I missed rent/mortgage payments; (3) I cut back on groceries, 
transportation, clothing, tuition; (4) I missed paying bills like heat, 
electricity, phone.  
197 313 
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CHAPTER V. FINDINGS 
Sample Characteristics 
The sample included 510 respondents ranging in age from 25 to 75 years old and over 
half the respondents identified as female (64.7%). Most respondents identified their 
race/ethnicity as White (70.8%), followed by African American (18.6%) and Hispanic (5.9%). 
The majority of respondents had at least some college education (81.3%) and just over half 
(59.5%) reported annual incomes under 300% FPL. Most respondents had health insurance 
through their provider (64.5%) followed by Medicare/Medicaid (54.1%); health insurance 
percentages total over 100 because categories were not mutually exclusive and some (17.5% ) 
respondents had multiple forms of insurance. The most common form of cancer reported was 
early breast cancer (22.4%) followed by prostate (10.2%) and colorectal (8.0%). Most 
respondents had been diagnosed over 4 years ago (44.3%) and had completed treatment (46.5%). 
See Table 2 for complete sample characteristics.  
Table 2 
Sample Characteristics 
Characteristic  % (N= 510) N 
Age (Years)  
 
 
 
 
    25-34 13.9 71 
     35-44 10.8 55 
     45-54 17.5 89 
     55-64 24.7 126 
     65-74 29.6 151 
     >75 3.5 18 
Gender  
 
  
    Female 64.7 330 
     Male 35.3 180 
Race/Ethnicity 
 
 
 
 
     African American  18.6 95 
     Asian 1.6 8 
     Hispanic 5.9 30 
     Pacific Islander 0.4 2 
     White 70.8 361 
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Characteristic  % (N= 510) N 
     Multiracial 2.0 10 
     Other  0.8 4 
Education  
 
  
     Less Than High School  1.4 7 
     High School Graduate (Or GED) 17.5 89 
     Some College 22.4 114 
     Associate’s Degree 10.6 54 
     Bachelor’s Degree 30 153 
     Master’s Degree 14.9 76 
     Doctorate/Professional Degree 3.4 17 
Annual Income  
 
 
 
 
     150%FPL 25.5 123 
     150 %-300% FPL 34.0 164 
     300% - 600% FPL 34.6 167 
     >600% FPL 6.0 29 
Insurance Type* 
 
  
     Private Through Employer 64.5 181 
     Private Through Healthcare.Gov 9.0 46 
     Medicare/Medicaid 54.1 276 
     Private Medigap 11.2 57 
     Tricare/Champus 4.1 21 
     Other  
 
5.7 29 
    Multiple  17.5 89 
Cancer Type    
     Bladder 3.5 18 
     Brain  2.2 11 
     Breast (Early) 22.4 114 
     Breast (Metastatic) 6.5 33 
     Colon Or Rectal  8.0 41 
     Endometrial, Cervical, Ovarian 6.7 34 
     Head / Neck 1.8 9 
     Kidney 4.9 25 
     Leukemia 4.7 24 
     Liver 0.4 2 
     Lung  5.3 27 
     Lymphoma 3.7 19 
     Melanoma 2.6 12 
     Myeloma 0.8 4 
     Pancreatic 2.4 12 
     Prostate 10.2 52 
     Stomach 0 0 
     Thyroid 4.9 25 
     Other (E.G. Esophageal, Intestinal,       
Sarcoma/Bone, Sebaceous, Testicular) 
8.8 45 
Time Since Dx  
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Characteristic  % (N= 510) N 
     <12 Months  14.3 73 
 13 Months – 2 Years 20.0 102 
     2 – 4 Years  21.4 109 
     >4 Years   44.3 226 
Treatment Status   
     In Active Treatment  20.2 103 
     Completed Treatment - On Maintenance  31.8 162 
     Completed Treatment  46.5 237 
Work Change   
     Continued Working Fulltime 8.6 44 
     Reduced Work Hours  91.4 466 
* Totals more than 100% because groups are not mutually exclusive 
Aim 1: Identify measurable characteristics of cost-coping, and delineate working measures 
of care-altering, lifestyle-altering and self-advocacy coping strategies.  
The 32 items selected for analysis were determined to be highly factorable (Bartlett p 
<.001, KMO=0.929). The principle axis factor analysis (PAF) with orthogonal varimax rotation 
resulted in four factors with Eigenvalues over 1.0, accounting for 45%, 29%, 11% and 8% of 
variance respectively. Examination of scree plot confirmed that a three- or four-factor structure 
was most appropriate (See Figure 4). For the final cost-coping model, items with the highest 
factor loadings from each factor were retained to produce an initial 25-item measure of cost-
coping (see Table 3 for a summary of the initial 25-item cost-coping measure).  
The first three factors were well-aligned with the hypothesized conceptual dimensions of 
care-altering, lifestyle-altering and self-advocacy cost-coping styles. The fourth factor that 
emerged was unexpected, but is theoretically viable as it contained three items related to 
financial help-seeking behavior, including: (1) applied for co-payment assistance; (2) applied for 
financial assistance for non-medical expenses; and (3) applied for financial assistance through 
provider. This factor was then tested as a coping strategy labeled Factor 4 “financial help-
seeking” in Aims 2 and 3, findings are outlined below.  
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Factor 1 was well-aligned with the concept of care-altering, the 10 items with factor 
loadings over 0.65 retained for this dimension include “how often (never, rarely, sometimes, 
often or always) did/do you do each of the following in order to reduce your expenses related to 
your cancer treatment: (1) postpone or skip medical appointments; (2) postpone or skip follow up 
testing; (3) postpone or skip bloodwork; (4) postpone or skip filling a prescription; (5) delay or 
skip complementary treatment; (6) postpone or skip psychological support; (7) skip dosage of 
prescribed drugs; (8) cut pills in half; (9) choose a lower cost medication; (10) order medication 
from outside US?” 
In Factor 2, items with factor loadings over 0.59 were retained. These 8 items were fairly 
well-aligned with the hypothesized cost-coping dimension of self-advocacy. The items retained 
for the self-advocacy domain include, “how often (never, rarely, sometimes, often, or always) 
did/do you do each of the following…(1) estimate cost before going to ER; (2) estimate cost 
before agreeing to treatment; (3) appeal a denial of benefit from you insurance company; (4) 
estimate cost before filling a prescription; (5) find out cost before filling a prescription for side 
effects/symptoms; (6) review the explanation of benefits from insurance company; (7) ask 
insurance company for help understanding coverage; (8) find out cost of lab test or scans before 
agreeing to testing.”  
In Factor 3, items with factor loadings over 0.5 were retained. These 4 items were 
conceptually well-aligned with the hypothesized cost-coping dimension of lifestyle-altering. The 
4 items retained for the lifestyle-altering domain include “which of the following have you 
experienced as a result of bills related to your cancer treatment (yes or no)… (1) I borrowed 
money from family/friends; (2) I missed rent/mortgage payments; (3) I cut back on groceries, 
transportation, clothing, tuition; (4) I missed paying bills like heat, electricity, phone.”    
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Figure 4. Screeplot of eigenvalues indicating four factor solution 
Aim 2: Identify behavioral, social and health system factors that predict variations in 
coping.  
The purpose of this analysis was to identify significant predictors of variations in cost-
coping identified in Aim 1: care-altering, lifestyle-altering, self-advocacy, and financial help-
seeking. Special emphasis was placed on behavioral characteristics, social factors, and features 
of the healthcare system. Independent predictors were similar across coping styles and variables 
from every domain were significantly associated with each outcome. A full summary of the 
independent predictors of each outcome are presented in Table 4. 
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Table 3  
Cost-coping Survey Items by Dimension 
Cost-Coping Survey Items by Dimension Factor Factor Loading 
How often (never, rarely, sometimes, often or always) 
did/do you do each of the following in order to reduce 
your expenses related to your cancer treatment: 
  
(1) postpone or skip medical appointments 1 0.84 
(2) postpone or skip follow up testing 1 0.85 
(3) postpone or skip bloodwork 1 0.83 
(4) postpone or skip filling a prescription  1 0.85 
(5) delay or skip complementary treatment 1 0.70 
(6) postpone or skip psychological support 1 0.75 
(7) skip dosage of prescribed drugs 1 0.87 
(8) cut pills in half 1 0.75 
(9) choose a lower cost medication 1 0.82 
(10) order medication from outside US 1 0.68 
(11) estimate cost before going to ER 2 0.75 
(12) estimate cost before agreeing to treatment  2 0.79 
(13) appeal a denial of benefit from you insurance 
company 
2 0.54 
(14) estimate cost before filling a prescription 2 0.84 
(15) find out cost before filling a prescription for side 
effects/symptoms 
2  0.81 
(16) review the explanation of benefits from 
insurance company 
2 0.58 
(17) ask insurance company for help understanding 
coverage 
2 0.64 
(18) find out cost of lab test or scans before agreeing to 
testing  
2 0.81 
(19) applied for co-payment assistance;  4 0.51 
(20) applied for financial assistance for non-medical 
expenses 
4 0.56 
(21) applied for financial assistance through provider  4 0.56 
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Cost-Coping Survey Items by Dimension Factor Factor Loading 
Which of the following have you experienced as a 
result of bills related to your cancer treatment 
(yes/no):  
  
(22) I borrowed money from family/friends  3 0.55 
(23) I missed rent/mortgage payments 3 0.60 
(24) I cut back on groceries, transportation, clothing, 
tuition 
3 0.51 
(25) I missed paying bills like heat, electricity, phone 3 0.70 
 
Predictors of Care-Altering 
Of 510 respondents, 123 (24%) reported that they had never engaged in any of the 10 
care-altering behaviors identified for this study, and another 218 (43%) reported that this 
question was not applicable to their situation. The remaining 169 respondents (33%) reported 
engaging in some form of this behavior at least once.   
Demographics. When all independently significant demographic factors were accounted 
for in a single model only age and income emerged as significant predictors of care-altering 
Specifically, individuals under 65 years old had twice the odds of those over to 65 to report care-
altering behavior, and individuals in the >150%FPL and 150%-300% FPL income brackets had 
3.2 and 2.7 times the odds of those in the >600% FPL bracket respectively.  
Behavioral. In unadjusted models, patient activation emerged as a significant predictor, 
where lower activation scores were associated with care-altering behavior. Such that every unit 
decrease in activation produced a 5% increase in the odds of care-altering. 
Health status.  Treatment status emerged as a significant predictor in the adjusted model 
of the health status domain. Individuals in active and maintenance treatment for cancer had twice 
the odds of those post-treatment to report care-altering.  
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Health system factors.  In the adjusted model of health system factors, high monthly out 
of pocket medical costs, difficulty anticipating out-of-pocket costs and ease of understanding 
insurance coverage emerged as a significant predictor of care-altering. Specifically, for every 
unit increase in out-of-pocket costs there was a 13% increase in the odds of care-altering, those 
who found it difficult to anticipate the out-of-pocket costs of treatments had twice the odds of 
those who found it easy to anticipate, and for every unit increase in ease of understanding 
insurance coverage there was a 30% reduction in odds of care-altering. 
Financial stress.  Higher levels of financial stress were associated with care-altering 
such that every unit increase in perception of financial stress produced a twofold increase in the 
odds of care-altering.  
Predictors of care-altering: final model.  When all of the significant predictors from 
each domain were accounted for in the final model, monthly out-of-pocket costs (OR = 1.09, p < 
.05), ease of understanding insurance coverage (OR = 0.73, p <.05) and financial stress (OR = 
1.76, p <.001) significantly predicted care-altering behavior. The final model is presented in 
Table 5. When accounting for other relevant variables, every unit increase in perception that 
insurance coverage is easy to understand produced a 27% reduction in odds of care-altering, 
while every unit increase in financial stress almost doubled the likelood of care-altering.  Final 
model of care-altering outlined in Table 6.  
Predictors of Self-advocacy 
Of 510 respondents, 82 (16%) reported that they never engaged in any form of self-
advocacy identified in this study. The remaining 428 (84%) engaged in self-advocacy at least 
once. On a scale of 8-40, where 40 represents maximum engagement in self-advocacy, the 
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average score was 17.8, indicating that although most of the respondents self-advocated on 
occasion, most did not rely on self-advocacy intensively.  
Demographics. Of the demographic variables, only age was significantly associated with 
self-advocacy behavior such that individuals under 65 years old had 2.6 times the odds of 
engaging in self-advocacy. 
Behavioral.  Patient activation was not significantly associated with self-advocacy.  
Health status.  After accounting for all the significant health status variables, in the 
adjusted domain model only cancer type was a significant predictor of self-advocacy. Specifially, 
individuals with thyroid cancer had 61% lower odds of engaging in self-advocacy compared to 
individuals with other cancer types.  
Health system factors.  After accounting for all significant health system factors, high 
monthly out-of-pocket medical costs and difficulty anticipating out-of-pocket treatment costs 
were significantly associated with self-advocacy.  For every unit increase in monthly out-of-
pocket costs there was a 30% in crease in the odds of self-advocacy. Individuals who reported 
difficulty anticipating out-of-pocket costs of treatment had 12 times the odds of engaging in self-
advocacy than those who did not perceive such difficulty.  
Financial stress.  Higher financial stress significantly predicted self-advocacy behavior 
such that every unit increase in financial stress increased the odds of self-advocacy 2.5 times.  
Predictors of self-advocacy: final model.  In the fully adjusted model, cancer type, 
monthly out-of-pocket costs, difficulty anticipating out-of-pocket treatment costs, and financial 
stress predicted self-advocacy behavior. Specifically people with thyroid cancer had 89% lower 
odds than individuals with other cancer types to engage in self-advocacy (OR = 0.21, p <.01).
  
Table 4 
Independent Predictors of Coping Strategy 
  Care-altering (n=292) Self-advocacy (n=510) Lifestyle-altering (n=510) Financial help-seeking 
(n=510) 
 
%/ 
M (SD) 
OR SE CI OR SE CI OR SE CI OR SE CI 
Age               
Under age 65 33% 2.32 0.49 1.53 - 3.52 2.64 0.65 1.63 - 4.27 4.44 1.02 2.84 - 6.96 3.72 0.73 2.53 - 5.48 
Education  
 
  
 
  
 
   
 
       
BA/BS 48% 0.85 0.18 0.57 - 1.28 1.30 0.32 0.81 - 2.10 0.58 0.11 0.41 - 0.84 0.66 0.12 0.46 - 0.94 
Gender  
 
  
 
   
 
       
      Female 64% 1.07 0.23 0.71 - 1.64 1.45 0.35 0.90 - 2.36 1.93  0.38 1.31 - 2.85 1.00 0.18 0.69 - 1.45 
Income  
 
  
 
   
 
 
 
    
150% 25% 2.77 1.21  1.17 - 6.54 0.97 0.46 0.36 - 2.64 4.57  2.39 1.64 - 
12.76 
1.94 0.81 0.85 - 4.40 
150-300 34% 2.60 1.10  1.14 - 5.95 1.45 0.74 0.54 - 3.92 3.31 1.71 .20 - 9.13 1.32 0.53 0.60 - 2.91 
300-600 35% 1.80 0.75 0.80 - 4.06 1.92 0.99 0.70 - 5.28 2.55 1.32 0.93 - 7.05 1.01 0.41 0.46 - 2.23 
((600)) 6%             
*Race / Ethnicity  
 
  
 
   
 
 
  
    
      African American  18% 2.06 0.64 1.12 - 3.79 2.04 0.76 0.98 - 4.24 2.38 0.55 1.51 - 3.73 2.77 0.73 1.67 - 4.61 
      Asian  2% 1.74 1.87 0.19 - 4.78 1.35 1.44 0.16 - 
11.09 
1.60 1.14 0.39 -    
6.48 
5.33 5.72 0.65 –  
4.64 
      Hispanic 6% 3.00 1.85 0.89 - 
10.07 
0.95 0.48 0.35 - 2.57 2.52 0.97 1.19 - 5.36 2.57 1.14 1.09 - 6.12 
      White  71% 0.45 0.12 0.27 - 0.74 0.59 0.17 0.33 - 1.04 0.37 0.07 0.25 - 0.54 0.33 0.07 0.21 - 0 
.50 Health Status 
*First diagnosed 
 
  
 
   
 
 
  
    
 12 months  14% 1.23 0.39 0.69 - 2.33 1.95 0.82 0.86 - 4.43 1.95 0.82 0.89 - 2.41 1.75 0.47 1.03 - 2.97 
13m – 2 years 20% 1.19 0.32 0.71 - 2.02 1.74 0.62 0.89 - 3.43 1.74 0.62 0.86 - 2.06 1.40 0.32 0.89 - 2.19 
      2-4 years 21% 1.79 0.51 1.03 - 3.12 0.70  0.19 0.40 - 1.20 0.70 0.19 0.68 - 1.61 1.60 0.36 1.02 - 2.49 
      >4 years 44% 0.55 0.11 0.37 - 0.84 0.72 0.17 0.45 - 1.15 0.66 0.12 0.46 - 0.95 0.45 0.08 0.31 - 0.64 
Reduced work hours 9% 
  
 9.05 9.22 1.23 - 
66.65 
4.86 1.71 2.44 - 9.70 8.49 4.52 2.99 - 
24.12 
*Treatment status 
 
  
 
   
 
 
  
    
      Active  20% 1.64 0.46 0.94 - 2.86 1.77 0.61 0.89 - 3.47 1.67 0.37 1.08 - 2.58 2.35 0.57 1.46 - 3.77 
      Maintenance 32% 1.55 0.35 0.96 - 2.40 1.96 0.57 1.11 - 3.46 2.08 0.40 1.42 - 3.04 1.71 0.34 1.16 - 2.52 
      Post 47% 0.52 0.11 0.35 - 0.79 0.44 0.11 0.27 - 0.71 0.35 0.07 0.24 - 0.51 0.36 0.07 0.25 - 0.52 
*Cancer type  
 
  
 
   
 
 
  
    
      Bladder 4% 1.24 0.80 0.18 - 1.28 0.37 0.19 0.13 - 1.00 0.78 0.40 0.29 - 2.13 0.59 0.28 0.23 - 1.51 
      Brain 2% 1.44 1.13 0.31 - 6.76 1.91 2.05 0.24 - 
15.34 
2.89 1.80 0.82 - 9.85 7.69 8.10 0.98 - 
60.57       Breast (early) 22% 0.65 0.15 0.41 - 1.02 1.35 0.41 0.74 - 2.46 0.88  0.18 0.53 - 1.27 0.68 0.15 0.4  - 1.04 
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 %/ 
M (SD) 
Care-altering (n=292) Self-advocacy (n=510) Lifestyle-altering (n=510) Financial help-seeking 
(n=510) 
OR SE CI OR SE CI OR SE CI OR SE CI 
      Breast (meta) 7% 1.85 1.00 0.59 - 3.63 1.41 0.78 0.48 - 4.15 2.28 0.83 1.11 - 4.66 1.33 0.49 0.64 - 2.77 
      Colorectal 8% 1.34 0.55 0.62 - 2.98 1.12 0.52 0.46 - 2.78 0.91 0.31 0.47 - 1.76 2.15 0.78 1.05 - 4.40 
      Female repro 7% 1.46 0.73 0.31 - 1.04 1.47 0.80 0.50 - 4.29 2.12 0.76 1.05 - 4.28 1.39 0.52 0.68 - 2.89 
      Leukemia 5% 3.65 2.72 0.85 - 
15.73 
1.35 0.70 0.32 - 2.87 1.63 0.68 0.72 - 3.70 2.32 1.11 0.91 - 5.95 
      Prostate 10% 0.56 0.17 0.30 -1.04 0.53 0.18 0.27 - 1.05 0.35 0.13 0.17 - 0.70 0.43 0.13 0.24 - 0.77 
      Thyroid 5% 2.95 2.20 0.57 - 5.07 0.38 0.17 0.16 - 0.92 1.77 0.73 0.79 - 3.97 0.80 0.33 0.36 - 1.79 
Health System Factors 
*Insurance type 
 
  
 
   
 
 
  
    
      Private  36% 0.78 0.17 0.51 - 1.17 1.61 0.43 0.95 - 2.73 0.84 0.16 0.57 - 1.22 0.74 0.14 0.51 - 1.07 
      Marketplace 9% 1.56 0.63 0.71 -3.45 2.94 1.79 0.89 - 9.72 1.66 0.52 0.91 - 3.06 1.61 0.53 0.84 - 3.06 
      Medigap 11% 1.55 0.56 0.76 - 3.19 1.44 0.60 0.62 - 3.24 1.17 0.52 0.67 - 2.06 1.44 0.42 0.81 - 2.55 
      Medicare/caid 54% 0.75 0.16 0.50 - 1.14 0.43 0.11 0.26 - 0.72 0.72  0.13 0.51 - 1.04 0.70 0.13 0.49 - 0.99 
      Multi 18% 0.72 0.19  0.44 - 1.21 1.14 0.37 0.60 - 2.18 0.73 0.13 0.26 - 0.73 0.55 0.13 0.35 - 0.87 
      Other 6% 1.23 0.58  0.49 - 3.10 1.21 0.67 0.41 - 3.57 0.43 0.12 0.20 - 1.16 1.24 0.49 0.57 - 2.67 
Monthly out-of-
pocket health costs 
(0-20)  
7.3 (4.8) 1.15 0.03 1.09 - 1.21 1.35 0.06 1.23 - 1.47 1.12 0.02 1.08 - 1.16 1.20 0.03 1.14 - 1.26 
Easy to understand 
insurance coverage 
(1-5) 
3.5 (1.1) 0.61 0.07 0.50 - 0.76 0.62 0.08 0.48 - 0.79 0.73 0.06 0.62 - 0.86 0.73 0.06 0.62 - 0.87 
Difficult to 
anticipate OOP cost 
of treatment  
26.3 2.93 0.85 1.66 - 5.18 17.84 12.91 4.32 - 
73.65 
3.01 0.62 2.00 - 4.52 1.76 0.37 1.17 - 2.66 
Financial Stress 
Financial stress [1-5] 2.4 (1.3) 2.10 0.22 1.71 - 2.58 2.49 0.35 1.89 - 3.27 3.26 0.35 2.65 - 4.02 2.10 
 
0.18 1.78 - 2.49 
Behavioral 
PAM [0-40] 32.4 
(5.9)  
0.95 0.02 0.91 -0.99 0.96 0.02 0.91 - 1.00 0.96 0.02 0.93 - 0.99 0.93 0.02 0.91 - 0.97 
 
4
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Every unit increase in monthly out-of-pocket costs (OR = 1.27, p < .001),  and financial stress 
(OR = 1.89, p < .001) increased the odds of self-advocacy by 27% and 89% respectively. People 
who found in difficult to anticipate the out-of-pocket costs of their treatment had 12 times the 
odds of engaging in self-advocacy (OR = 12.10,  p < .001). The final model is presented in Table 
5. 
Predictors of Lifestyle-Altering 
Of 510 respondents, the majority (61.4%, n=313) did not report having engaged in 
lifestyle-altering activities in response to cancer treatment costs. Another 25% (n=125) reported 
at least one lifestyle-altering event, while 19 individuals endured all four major lifestyle-altering 
events.  
Demographics. Among demographic variables, age, gender, race/ethnicity, and 
household income emerged as significant predictors of lifestyle-altering in independent and 
adjusted domain models. Individuals under 65 years old had 3.7 times the odds of lifestyle-
altering than older adults, women had 1.9 times the odds of men, people in the <150% FPL 
income bracket had twice the odds of those in the highest income bracket to engage in care-
altering. People identifying as White had 60% lower odds than non-White respondents of 
experiencing lifestyle-altering. 
Behavioral.  Lower patient activation level was marginally associated with lifestyle 
altering in independent models such that every unit increase in activation reduced the odds of 
lifestyle-altering by 5%.  
Health status. After accounting for all significant predictors of lifestyle-altering in the 
health status domain, employment changes and cancer type remained significant. Individuals 
who reported reduced work hours during treatment had 3.3 times the odds of experiencing 
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lifestyle-altering. People with cancers of the female reproductive system had 2.4 times the odds 
and individuals with prostate cancer had 60% lower odds of experiencing lifestyle-altering.  
Health system factors. Among factors related to the health system, insurance coverage, 
monthly out- of-pocket costs, and difficulty anticipating treatment costs were significantly 
associated with lifestyle-altering in the domain adjusted model. Having multiple forms of 
insurance reduced the odds of lifestyle-altering by 53%, while every unit increase in monthly 
out-of-pocket costs increased lifestyle -altering by 10%. Individuals who found it difficulty to 
anticipate treatment costs had 2.6 times the odds of lifestyle-altering.  
Financial stress.  For every unit increase in reported financial stress the odds of lifestyle-
altering increased 3.3 times.  
Predictors of lifestyle-altering: final model.  In the final adjusted model, gender, 
race/ethnicity, financial stress and difficulty anticipating treatment costs were significant 
predictors of lifestyle-altering. Women had twice the odds of men (OR = 2.00, p < .01), and 
White people had half the odds of those identifying as another race/ethnicity (OR = 0.50, p <.05) 
of lifestyle-altering in response to treatment costs. Those who found it difficult to anticipate 
treatment costs had almost twice the odds of lifestyle altering than those who did not (OR = 1.85, 
p < .05), and every unit increase in financial stress increased the odds of lifestyle-altering 
threefold (OR =2.90, p < .001). The final model is presented in Table 5. 
Predictors of Financial Help-Seeking Behavior 
Of 510 respondents, 218 had never engaged in financial help-seeking, while another 87 
felt that this question was not applicable to their experience. The remaining 203 individuals 
(39.8%) engaged in some form of financial help-seeking activity at least once.  
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 Demographics.  In the domain adjusted demographics model only age and ethnicity were  
significantly associated with financial help-seeking. Individuals under 65 had almost three times 
the odds of engaging in financial help-seeking than those over 65 and individuals identifying as 
white had 58% lower odds of financial help-seeking. 
 Health status.  Among variables related to health status, employment changes and cancer 
type were significantly associated with financial help-seeking. Individuals who experienced 
reduced work hours had nearly six times the odds of seeking out financial assistance and 
individuals with prostate cancer had nearly half the odds of those with other cancers.  
 Behavioral.  Higher patient activation scores increased the odds of financial help-seeking 
such that unit increase in patient activation score odds of financial help seeking decreased the 
odds of financial help-seeking by 6%.   
 Health system factors.  Among health system factors understandability of insurance 
coverage and monthly out-of-pocket treatment costs were associated with financial help-seeking. 
For every unit increase in understandability of insurance coverage odds of financial help-seeking 
decreased by 19%. Similarly for every unit increase in monthly out-of-pocket costs the odds of 
financial help-seeking increased by 20%.   
 Financial stress.  Financial stress was significantly associated with financial help-
seeking behavior such that every unit increase in difficulty paying bills due to cancer doubled the 
odds of financial help seeking.  
Predictors of financial help-seeking: final model. In the fully adjusted model of all five 
domains, financial help-seeking was significantly predicted by age, patient activation score, 
financial stress and high monthly out-of-pocket treatment costs. Individuals under 65 years old 
were almost twice as likely to engage in financial help-seeking (OR = 1.63, p < .001), and for 
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every unit increase in patient activation the odds of financial help-seeking decreased by 5% (OR 
= 0.95, p <.05). For every unit increase in financial stress the odds of financial help-seeking 
nearly doubled (OR = 1.57, p <.001) and for every unit increase in monthly out-of-pocket 
medical costs the odds of financial help-seeking increased 10% (OR = 1.10, p <.001). The final 
model of financial help-seeking is presented in Table 5.  
Table 5 
Final Models Predicting Each Cost-coping Strategy 
  
Predictors of Care-Altering: Final Model 
  Predictors   OR SE 95% Confidence Interval P 
Monthly OOP [0-20] 1.09 0.04 1.06 - 1.22 <.001 
Financial stress [1-5]  1.73 0.22 1.40 - 2.22 <.001 
Ease of understanding insurance [1-5] 0.73 0.09 0.57 - 0.92 <.01 
Predictors of Self-Advocacy: Final Model 
Predictors OR SE 95% Confidence Interval P 
Monthly OOP [0-20] 1.27 0.06 1.16 - 1.34 <.001 
Difficult to anticipate tx cost  12.09 8.51 2.83 – 51.60 <.001 
Financial stress [1-5] 1.89 0.31 1.37 - 2.47 <.001 
*Thyroid cancer  0.21 0.12 0.07 - 0.67 <.01 
 
Predictors of Lifestyle-Altering: Final Model 
Predictors OR SE 95% Confidence Interval P 
Gender (female)  2.00 0.53 1.32 - 3.48 <.05 
*Race/Ethnicity (White) 0.50 0.14 0.29 - 0.86 <.05 
Difficult to anticipate tx cost 1.85 0.51 1.07 – 3.15 <.05 
Financial stress [1-5] 2.90 0.37 2.49 - 3.85 <.001 
 
Predictors of Financial Help-Seeking: Final Model 
Predictors  OR SE 95% Confidence Interval   P                            
Age (under 65) 1.63 0.37 1.17-2.99 <.001 
Patient Activation Score 0.95 0.02 0.91-0.99 <.05 
Financial stress [1-5]  1.67 0.16 1.38-2.03 <.001 
Monthly OOP [0-20] 1.10 0.03 1.07-1.20 <.001 
*Categorical dummy variable compared to members of all other categories;  
Binary variable compared to null option; 
 OOP refers to out-of-pocket costs 
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Aim 3: Analyze quantitative survey data to measure the extent to which each cost coping 
strategy mediates and/or moderates the relationship between financial stress and strain. 
Correlations.  Highly significant, positive correlations were found between financial 
stress and strain (r = 0.63, p < .001), financial stress and care-altering (r = 0.56, p  < .001), 
financial stress and lifestyle-altering (r = 0.59, p < .001), and financial stress and self-advocacy 
(r = 0.49, p < .001). Similarly significant correlations were found between financial strain and 
care-altering (r = 0.43, p < .001), financial strain and lifestyle-altering (r = 0.47, p < .001), and 
financial strain and self-advocacy (r = 0.39, p < .001).  
In order to test the overall fit of the hypothesized mediation and moderation models 
Hayes’ PROCESS method (specifically Models 1 and 4) was employed. First, variables were 
tested for normality and transformed to meet assumptions of linear regression. The distributions 
of each of the three coping variables were found to be zero-inflated. As such, the null responses 
in care-altering, lifestyle-altering and self-advocacy were dropped from analyses in order to 
comply with the assumption of normality required for regression-based analyses. Removing the 
null responses did not significantly reduce statistical power, and it also made more sense 
conceptually to measure the extent of mediation and moderation using responses that affirmed 
some cost-coping behavior. Descriptions of each variable are presented in Table 6.  
Mediation.  Simple mediation models using the PROCESS method (Model 4) were 
implemented testing care-altering, lifestyle-altering, self-advocacy and financial help-seeking 
coping strategies as independent mediators of financial stress’ impact on financial strain. Model 
results indicated the presence of a significant mediating effect for lifestyle-altering only (p < 
.05). The a path was significant, such that financial stress was positively associated with 
lifestyle-altering (B = 0.43, p < .001). As were the c (B = 0.54, p < .01) and c’ (B = 0.46, p < .01) 
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paths which show the total and direct effect of stress on strain.Lifestyle-altering accounted for a 
small but significant indirect effect of stress on strain (B = 0.08, p < .05). This finding suggests 
that financial stress may increase strain via lifestyle-altering. See Figure 5. 
Table 6 
Descriptive Summary of Variables Tested for Mediation/Moderation 
Variable N Range  M (SD)  
Financial Stress  510 [1-5] 2.43 1.28 
Financial Strain 510 [1-5] 2.53 1.26 
Care-altering#  168 [11-50] 23.44 10.24 
Lifestyle-altering# 197 [1-4] 1.69 1.02 
Self-advocacy# 428 [9-40] 21.14 7.35 
Financial help-seeking# 205 [4-15] 8.54 3.11 
#Null responses removed  
Moderation.  Moderation models using the PROCESS method (Model 1) to identify the 
presence of significant and independent interaction effects between financial stress and each of 
the constructs of interest, care-altering, lifestyle-altering and self-advocacy coping styles 
respectively. Results indicated that only self-advocacy yielded a significant interaction effect  
with financial stress in predicting financial strain. The main effect of self-advocacy on financial 
strain was significant and positive (B = .05, p < .05), while the interaction effect of self-advocacy 
and financial stress was significant and negative (B = -.01, p < .01). Suggesting that self-
advocacy may dampen the effect of financial stress on strain. See Figure 6.  
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Figure 5. Simple mediation model with lifestyle-altering as mediator 
 
 
Figure 6. Relationship between stress and strain moderated by self-advocacy 
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Post-Hoc Analyses 
While completing the analyses, an issue emerged that called for post-hoc analyses. In 
Aim 2, financial stress was a significant independent predictor of all coping outcomes. When 
financial stress was added to the final models, relationships between variables from other 
domains and the outcome variables were either diminished or rendered inert across all four 
coping outcomes. Financial stress is a powerful downstream indicator of all four coping 
strategies and it could be a clinically useful measure. In order to hone in on more upstream 
determinants of financial toxicity post-hoc analyses were conducted to model significant 
predictors of financial stress.  
Post-hoc Analysis Methods 
The same methods of modeling the cost-coping outcomes in outlined Aim 2 were used to 
model significant predictors of financial stress. I determined that logistic regression would yield 
the most readily interpretably results for this research question. As such, the outcome variable, 
financial stress, was modified from an ordinal (1-5) to a binary variable (0-1). The ordinal 
financial stress measure was recoded in such a way that responses to the question “To what 
degree has your cancer treatment caused you financial hardship (i.e. difficulty paying your 
bills)?” were coded as “1” if the response was “a little,” “some,” “a lot,” or “an extreme amount” 
and coded as “0” if the response was “none.” Step-wise logistic regression was then performed 
using the variables from four predictor domains – (1) demographics; (2) behavioral; (3) health 
status; and (4) health system factors. Each predictor domain was modeled with the binary 
financial stress outcome to identify significant predictors from each domain. The signficant 
predictors from each domain were reserved and tested in a final, multi-domain model of financial 
stress.  
 50 
 
Post-hoc Analysis Findings: Predictors of Financial Stress 
Demographics.  Age, income, and race/ethnicity were significant predictors of financial 
stress in the adjusted domain model. Individuals under 65 years old were nearly six times more 
likely than those over 65 to experience financial stress, individuals in the <150% FPL and 150%-
300% FPL income brackets were 2.9 and 2.2 times more likely to report financial stress than 
those in the >600%FPL bracket. White respondents were half as likely as non-White respondents 
to report financial stress.  
Behavioral.  Activation scores were independently associated with financial stress, for 
every unit increase in activation score the odds of financial stress decreased by 5%.  
Health status.  Among health status variables, employment change, cancer type and time 
since diagnosis emerged as significant predictors of financial stress both independently and in 
adjusted domain models. Individuals with reduced work hours were seven times more likely to 
report financial stress than those who did not work less, those diagnosed in the last 12 months 
were two times more likely to experience financial stress than those diagnosed more than 12 
months ago, and those with early breast cancer and prostate cancer had approximately half the 
the odds of those with other cancer types.  
Health system factors.  Among health system factors, monthly out of pocket costs, 
insurance type, ease of understanding insurance and difficulty anticipating out-of-pocket costs 
were significantly associated with financial stress in the adjusted domain model. Specifically, 
every unit increase in monthly OOP costs increased the odds of financial stress by 25%; having a 
plan purchased on the Affordable Care Act marketplace increased the odds of financial stress 2.3 
times; difficulty anticipating treatment costs increased the odds of financial stress 2.5 times; and 
ease of understanding insurance coverage decreased the odds of stress by 23%.   
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Table 7  
Predictors of Financial Stress 
Predictors of Financial Stress: Final Model 
Predictors   OR SE 95% Confidence 
Interval 
P 
Age (under 65)                                 3.15 0.86 2.05 - 5.57 <.001 
*Race/Ethnicity 
(White)  
                               0.44 0.12 0.26 - 0.77 <.01 
Income ((>600% FPL)     
       <150% FPL 5.18 1.90 2.52 - 10.65 <.001 
        150% - 300% FPL 2.69 0.87 1.42 - 5.06 <.01 
Reduced work hours  4.21 2.57 1.28 - 13.90 <.05 
*Diagnosed in last 12 months 2.09 0.71 1.07 - 4.07 <.05 
Monthly OOP [0-20] 1.21 0.04 1.10 - 1.24 .<.001 
Ease of understanding insurance coverage 
[1-5] 
0.76 0.08 0.57 - 0.89 <.01 
Difficult to anticipate OOP cost of 
treatment  
1.90 0.48 1.01 - 3.01 <.05 
*Categorical dummy variable compared to members of all other categories   
Binary variable compared to null option 
 
Predictors of financial stress: final model.  In the final adjusted model, age, income, 
race/ethnicity, reduced work hours, monthly out-of-pocket medical costs, time since diagnosis, 
difficulty anticipating out-of-pocket treatment costs and ability to understand insurance coverage 
predicted financial stress. Specifically, those under 65 years old were three times more likely to 
report financial stress than those over 65 (OR = 3.15, p <.001). White respondents were half as 
likely as non-Whites (OR = 0.44, p <.001) to report stress, and those with annual household 
incomes <150% FPL (OR = 5.18, p < .001) and 150%-300% FPL (OR = 2.69, p <.001) were five 
and three times more likely to report financial stress than those in the >600% FPL bracket. 
People who reduced work hours were four times more likely to report financial stress than those 
who had not reduced work hours (OR = 4.21, p<.05). Individuals diagnosed in the last 12 
months had twice the odds of those diagnosed more than 12 months ago (OR = 2.09, p <.05). For 
every unit increase in monthly out-of-pocket costs, the odds of financial stress increased by 20% 
(OR = 1.20, p <.001). Those who found it  difficult to anticipate out-of-pocket treatment costs 
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were almost twice as likely to report financial stress (OR = 1.89, p < .05). For every unit 
increase in ease of understanding insurance coverage the odds of financial stress decreased by 
23% (OR = 0.77, p < .05). The final model predicting financial stress is presented in Table 7.  
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CHAPTER VI. DISCUSSION 
The overall goal of this dissertation is to advance knowledge of the coping strategies that 
insured cancer patients and survivors use to balance the financial needs of their household with 
the direct and indirect costs of having cancer. This exploratory study aimed to develop a model 
of financial hardship and coping that can be used to identify modifiable behavioral and social 
factors associated with successful coping (i.e. coping that reduces psychological distress). In 
doing so, we hoped to generate testable hypotheses on social and psychological aspects of cost-
coping, and contributes to the theoretical knowledge of financial hardship as a social determinant 
of health. This section offers interpretations of the study findings and possible future directions 
in light of the current literature on financial toxicity and the methodological limitations of the 
study.  suggest that the goals and aims were effectively achieved. 
Exploratory factor analysis revealed a four factor solution for items related to cost-coping 
in a survey of cancer patients and survivors. Each factor aligned to a hypothesized problem-
focused coping strategy and were given the following concept labels: care-altering, lifestyle-
altering, self-advocacy and financial help-seeking. Two of these factors identified were well-
aligned with measures of lifestyle-altering and care-altering used in past studies (Nipp et al., 
2016; Zullig et al., 2013). The first dimension identified in the factor analysis comprised ten 
items that are highly consistent with the unvalidated survey items used to measure care-altering 
in a study conducted by Nipp and colleagues (2016). The second cost-coping strategy identified, 
lifestyle altering, was narrowed down to four items – (1) borrowing money from friends and 
family, (2) missing rent/mortgage payments, (3) missing essential utility payments, and (4) 
cutting back spending on groceries, transportation, clothing and/or tuition. Despite minor 
differences, this categorization is well-aligned with the unvalidated measures of lifestyle-altering 
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used in external studies (Nipp et al., 2016; Zullig et al., 2013). Additionally, two factors emerged 
that have not yet been explicitly measured in the context of cancer financial toxicity: self-
advocacy and financial help-seeking.  
The third cost-coping strategy consisted of eight survey items that are best described 
using the term financial self-advocacy, but specifically measure the actions people took to 
prepare for medical costs before agreeing to a treatment. These items reflect a certain level of 
knowledge about how the fee-for-service health care system operates. Although self-advocacy 
has been promoted as a necessary skill for cancer patients and survivors (Hagan & Donovan, 
2013; Walsh-Burke & Marcusen, 1999), it has not been well-studied in relation to cancer-related 
financial behaviors and responses to financial hardship.  
The fourth dimension of cost-coping emerged unexpectedly. It contained three items 
related to asking for financial and copayment assistance from treatment providers and non-profit 
organizations which seemed to describe financial help-seeking. There is very little empirical 
research on financial help-seeking and the role of financial assistance programs in reducing 
financial stress and toxicity. The proportion of cancer patients in the general population seeking 
financial assistance is uncertain, however nearly 40% of the respondents in this relatively study 
reported reaching out to various patient financial assistance programs for help with their medical 
bills. The limited number of studies in this area suggest a lack of transparency and consistency in 
patient financial assistance programs  (Zafar, Peppercorn, Asabere, & Bastian, 2017), and the 
possiblility that they increase overall drug costs and reinforce existing cancer health disparities 
(Zafar & Peppercorn, 2017; Zullig, Wolf, Vlastelica, Shankaran, & Zafar, 2017). More research 
should be conducted on this important, heavily relied upon aspect of the cancer support network. 
 55 
 
Together, these findings suggest that there are at least four distinct behavioral responses 
to financial stress in cancer, however further research is needed to validate this measure and the 
underlying concepts. Past studies on financial toxicity have largely emphasized two cost-coping 
strategies: care-altering and lifestyle-altering (Nipp et al., 2016; Zullig et al., 2013). Findings 
from this study lend empirical support to the unvalidated measures of care-altering and lifestyle-
altering used in those studies. Findings from this study go on to suggest two additional cost-
coping behaviors: self-advocacy and financial help-seeking. There is little research on these two 
coping strategies in the literature on financial toxicity in cancer and more should be conducted to 
understand their role in containing or proliferating financial toxicity.  
These four coping strategies were found to vary somewhat by social, behavioral and 
health system factors, but seemed to have more commalities than differences. Findings shed light 
on a number of common predictors of cost-coping. Financial stress, measured here as “difficulty 
paying one’s bills due to cancer,” was a strong predictor of all four strategies. High monthly out-
of-pocket costs, difficulty anticipating out-of-pocket treatment costs or understanding what was 
covered by one’s health insurance were also important predictors. Financial stress was such  a 
strong common predictor that post hoc analyses were conducted to identify factors associated 
with financial stress. These were found to be age (being younger than 65), race/ethnicity 
(identifying as non-White), income (annual household income  300% FPL), reducing work 
hours due to cancer, high monthly out-of-pocket costs and difficulty understanding insurance or 
anticipating out-of-pocket costs. Differences in the measurement of financial stress make it 
difficult to link this finding perfectly to those of past studies, however a 2017 systematic review 
conducted by Gordon et al. identified the following determinants of financial stress among 25 
studies: identifying as female, African American or Hispanic, younger age, low income or 
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reduced work hours, and having high out-of-pocket costs or no health insurance. Results from 
the current study lend support to those of past studies and go on to suggest that the 
understandability and interpretability of insurance coverage may also play a role in financial 
stress and cost-coping.  
Findings shed light on the cost-coping processes of cancer patients and survivors and 
contribute to the literature on the structural basis of exposure to cancer-related financial stress. It 
was determined that only two cost-coping strategies played meaningful roles in the relationship 
between financial stress (i.e. difficulty paying one’s bills due to cancer) and financial strain (i.e. 
psychological distress attributed to cancer-related financial hardship), and could therefore be 
implicated in the stress process. Lifestyle-altering was found to significantly mediate (B = 0.08, p 
< .05) the positive, linear relationship between stress and strain, explaining its effect. One the 
other hand, self-advocacy was found to interact significantly (B = -0.01, p < .01) with financial 
stress to buffer its effect on financial strain.   
The individuals most likely to report lifestyle-altering experiences in this sample were 
women, individuals identifying as non-White, and those who experience reduced employment 
during cancer treatment. Lifestyle-altering was the only strategy explored in this study that was 
significantly associated with gender, race/ethnicity in fully-adjusted models. These findings 
contribute to the growing evidence on race- and gender-based disparities in cost-coping. For 
example, in a large sample of women with a history of breast cancer Jagsi and colleagues (2015) 
found that racial and ethnic minorities were more likely to endure both care- and lifestyle-
altering experiences, which they called privations. In light of these findings, the term privation 
may be preferable to lifestyle-altering because it more accurately captures the distress that these 
experiences can cause. Furthermore, its role in proliferating financial stress via mediation may be 
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sufficient reason to rethink labeling it as a “coping strategy.” There is limited research on the 
experiences of people who experience privations and life alterations related to cancer treatment 
cost. Future studies should explore the situational contexts and decision making processes 
involved in lifestyle-altering to better understand how these outcomes can be averted.  
These findings point to a meaningful inequity in the health system in which women, 
people of color and individuals without adequate employment protections are more likely to 
seriously alter their lifestyles to accommodate the cost of their treatment in ways that pose a 
threat to their mental health and wellbeing. These results are consistent with the literature on 
cancer health disparities in suggesting that these populations may be unduly burdened, materially 
and psychologically, by inefficiencies in the current American health care system. (Glanz, 
Croyle, Chollette, & Pinn, 2003).  
Study Limitations 
As a secondary analysis of survey data this study has certain limitations that should guide 
interpretation of these findings. Because 3000 invitation emails were sent, the final sample of 
511 represents a 17% response and inclusion rate. This accounts for individuals who were ruled 
out because they did not have a history of cancer, were under 25 years old, or did not have health 
insurance. The remaining were self-selected to participate in an online survey which limited the 
sample to individuals who engage in market research with access to the internet. The result was a 
sample distribution that should be considered marginally representative of the U.S. population of 
cancer patients and survivors, where only 78% of the population has access to a home computer 
with broadband internet access (U.S. Census Bureau, 2017). Further, since the survey was only 
provided in English, findings should not be generalized to individuals who do not read English. 
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Similarly, some individuals may have been too fatigued or seriously ill to participate, these 
findings cannot be thought to represent that subpopulation of cancer patients.  
In addition to being reliant on self-report, another limitation of this study is that measures 
of cost-coping, stress, and strain were not validated instruments. This is because the survey was 
originally designed to collect in-depth descriptive data on American cancer patients and 
survivors and was not aimed at testing correlational or causal relationships. Many variables were 
categorical or ordinal where continuous measures would have allowed for more granular 
analyses.  For example, a more precise measure of objective financial stress could have been 
generated using a ratio of annual household income to monthly out-of-pocket expenses if these 
data points had been collected using continuous rather then ordinal/categorical response options. 
Further, if data on household size and marital status had been collected, analyses using annual 
household income would have been interpreted more effectively. In light of these limitations, 
findings should be considered exploratory rather than conclusive, suggesting areas for further 
exploration and serving to generate hypotheses and research questions for future studies. 
Implications for Policy 
Findings suggest that cancer-related financial stress represents a significant psychosocial 
burden that affects several vulnerable populations that social workers serve. Women, people of 
color, the poor and underinsured are unduly burdened by the material and psychological costs of 
cancer treatments. Cancer patients, especially those from traditionally marginalized backgrounds, 
would benefit from guaranteed access to high-quality insurance plans with minimal or zero cost-
sharing requirements.  
The importance of health insurance type and quality in predicting financial stress was 
seen in findings throughout this study. Bivariate analyses in this study showed that having 
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Medicare or Medicaid insurance coverage reduced the risk of engaging in lifestyle-altering and 
financial help-seeking strategies. Younger patients and survivors, specifically those under 65 
years old and therefore not qualifying for Medicare, were more likely to report financial stress. 
This has been found repeatedly in past studies (Banegas et al., 2016; Shankaran & Ramsey, 
2015; Yabroff et al., 2015; Zafar et al., 2013) and has been attributed, at least in part, to the 
protective effect of Medicare for older adults (Yabroff et al., 2015). Further, individuals 
reporting household annual incomes 300% above the federal poverty line were more likely to 
report financial stress. Despite living just above the poverty line, people who earn above 138% 
FPL are not eligible for Medicaid in many states and must rely on either employer-sponsored or 
Marketplace insurance plans, which vary greatly in cost-sharing requirements (Buttorff, 
Andersen, Riggs, & Alexander, 2015; Graves & Mishra, 2016; Thorpe, Allen, & Joski, 2015). As 
a possibly remedy to underinsurance and financial stress, policy makers have been exploring the 
expansion of public insurance options through Medicare (Friedman, 2013) or Medicaid 
(Wikelius & O’Toole, n.d.).   
 Factors related to the understandability of insurance and ability to anticipate out-of-
pocket costs were also important in predicting financial stress and cost-coping. Health service 
researchers are exploring the utility of price transparency tools and cost of care discussions for 
reducing health care spending, but at this time there is limited evidence that cancer patients and 
survivors will benefit from these interventions (Henrikson & Shankaran, 2016; Shih, Nasso, & 
Zafar, 2018; Sinaiko & Rosenthal, 2016). Furthermore, although it’s generally a good idea to 
understand the details of one’s health insurance coverage, there is limited evidence to suggest 
that health insurance literacy reduces financial stress in cancer. In fact there is some evidence 
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that the effort needed to access and understand health insurance and cost information is highly 
burdensome for cancer patients and survivors (George, Grant, James, Mir, & Politi, 2018).   
Implications for Practice 
In the absence of a robust policy response, clinical interventions are needed to bolster 
effective coping and to target material resources and psychological support where they are most 
beneficial. Clinical programs aimed at reducing financial hardship should be adapted to reflect 
emerging distinctions in coping style. Social workers and other psychosocial oncology providers 
need the tools to (1) identify individuals at risk for financial stress and (2) identify individuals 
using risky or distressing coping strategies like care-altering and some life-altering behaviors. 
Providers will then be prepared to deliver targeted psychosocial support that can include material 
or specialized behavioral interventions.  
This study outlined important predictors of financial stress and coping that might be 
useful as clinical indicators of patients at risk of financial toxicity. As stated previously, certain 
patient populations may be at greater risk. These include women, people of color, those with 
annual household incomes below 300% FPL (< $75,000 / year ) and individuals with high 
deductible insurance plans who are likely to incur high out-of-pocket costs related to treatment. 
Financial stress can be measured by the question “have you had difficulty paying your bills due 
to cancer treatment?” These indicators can be used to inform the development of screening tools 
for the early identification of financial toxicity in clinical practice.    
This study highlighted the benefits of financial self-advocacy, a coping strategy shown to 
decrease financial strain/distress. Oncology social workers and financial navigators can teach 
self-advocacy skills, help people make sense of their coverage and plan appropriately for the out-
of-pocket costs of treatment. As such, these findings may inform the development of evidence-
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based patient-education, screening and decisional support tools that support optimal problem and 
emotion focused coping.  
Implications for Research 
To date, few studies have examined the ways that people cope with treatment-related 
financial stress. Future research would benefit from the development of a valid and reliable scale 
of cost-coping. The preliminary measure developed in this dissertation offers a beginning for 
developing such a scale. In this study, however, only problem-focused coping strategies were 
identified. Recent studies have begun to identify other coping strategies that should be explored 
in greater depth and adequately measured (Head et al., 2018). In particular, emotion-focused 
coping and social support may have positive impacts on health and mental health outcomes in 
financially burdened cancer patients that deserve greater attention.  
Financial help-seeking emerged as a distinct strategy for a large subset of respondents in 
this study. In general, financial assistance programs have not been well-examined in the 
scholarly literature despite the reliance of them in clinical practice. Support for the effectiveness 
of financial assistance programs has been largely anecdotal, suggesting a need for more 
extensive evaluation studies. The universe of cancer financial assistance programs should be 
mapped out to better understand how these programs can be optimized to meet the growing 
financial needs of cancer patients and to target subpopulations more precisely.  
Conclusion 
 This dissertation sought to (1) identify distinct problem-focused coping strategies by 
testing the underlying factor structure of commonly used measures of cost-coping; (2) model the 
social, behavioral and health system factors that predict coping strategy variations; and (3) 
identify the role that cost-coping plays in the relationship between financial stress and strain. In 
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summary, the findings of this dissertation suggest that individuals affected by cancer cope with 
the out-of-pocket costs of their care differently, often according to the cultural and social 
positions. Cost-coping strategies vary and can either buffer or proliferate stress, and as a result, 
can have serious impacts on health and mental health. The findings should be interpreted in light 
of the its limitations as a cross-sectional study with a relatively small sample. Future studies are 
needed to develop, evaluate and implement screening tools for the identification of cancer 
patients and survivors at risk of encountering financial stress, and to develop interventions that 
support self-advocacy and prevent the need to rely on care-altering and lifestyle-altering cost-
coping strategies. 
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APPENDIX 
 
Appendix 1. CancerCare Survey 4 - Financial and Insurance Issues 
 
(Note: Programming instructions in blue)  
Thank you for participating in our survey. 
The purpose of this study is to learn about the impact of healthcare insurance and 
financial issues on people with cancer. The information you provide will be used to 
create support programs and influence policy to assist people with cancer. 
 
As you answer the questions in this survey please base your answers on your personal 
experiences and knowledge about healthcare insurance and finances related to your 
cancer treatment. 
 
The survey should take approximately 20 minutes to complete. All of your responses 
will remain confidential and will not be tied to any information that could identify you. 
 
First, please tell us a little bit about yourself: 
 
 
(PN: Force a single response.) 
1. What is your age? 
 
❑ Under 25 years (Thank and terminate respondent) 
❑    25 to 34 years 
❑    35 to 44 years 
❑    45 to 54 years 
❑    55 to 64 years 
❑    65 to 74 years 
❑ 75 or older 
 
 
(PN: Allow entry of 5-digit ZIP code) 
2. What ZIP code do you live in? 
 
 
 
(PN: Force a single response.) 
3. What is your current cancer status? 
 
❑ Diagnosed but do not have a plan for treatment (Thank and terminate respondent) 
❑ Diagnosed and have a plan for treatment but not yet begun treatment 
❑ In active treatment 
❑ Completed treatment and on maintenance therapy 
❑ Completed treatment and not on maintenance therapy 
❑ I do not have cancer / have never had cancer (Thank and terminate respondent❑   
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Other Please specify     
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(PN: Force a single response but allow multiple responses.) 
4. What type of health insurance do you have? Please select all that apply. 
 
❑ Commercial/Private insurance through an employer 
❑ Private insurance via Healthcare.gov (the insurance exchange) 
❑ Medicare/Medicaid 
❑ Private Medigap 
❑ Tricare/Champus 
❑ I don’t have health insurance (Thank and terminate respondent) 
❑ Other (please specify)     
 
 
(PN: Force a single response.) 
5. How long ago were you first diagnosed with cancer? 
 
❑ Within the last 12 months 
❑ Between 13 months and 2 years ago 
❑ Between 2 years and 4 years ago 
❑ More than 4 years ago 
 
 
(PN: 50% of the completes per region must be either Breast or Lung or Prostate or Colon/Rectal. 50% of 
the completes per region must be from all other forms of cancer. Thank and terminate respondent once 
quota is reached.) 
(PN: Per region, an individual cancer type can account for no more than 35% of the regional 
completions. Thank and terminate respondent once quota is reached.) 
(PN: Force a single response.) 
6. What type of cancer were you most recently diagnosed with? 
 
❑ Bladder 
❑ Brain 
❑ Breast (Early Stage) 
❑ Breast (Metastatic) 
❑ Colon or rectal 
❑ Endometrial, cervical, or ovarian 
❑ Head/neck 
❑ Kidney 
❑ Leukemia 
❑   Liver 
❑   Lung 
❑ Lymphoma 
❑ Melanoma 
❑ Myeloma 
❑ Pancreatic 
❑ Prostate 
❑ Skin (Thank and terminate respondent) 
❑ Stomach 
❑ Thyroid 
❑ Other (please specify)     
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(PN: Display all statements on 1 screen.) 
(PN: Force a single response for each statement.) 
7. Below are some statements that people sometimes make when they talk about their health. Please 
indicate how much you agree or disagree with each statement as it applies to you personally. If the 
statement does not apply to you, please select N/A (not applicable). 
 
  
Disagree 
Strongly 
 
Disagree 
 
Agree 
 
Agree 
Strongly 
 
N/A 
a. When all is said and done, I am the person who 
is responsible for taking care of my health 
❑ ❑ ❑ ❑ ❑ 
b. Taking an active role in my own health care is 
the most important thing that affects my health 
❑ ❑ ❑ ❑ ❑ 
c. I know what each of my prescribed medications 
do 
❑ ❑ ❑ ❑ ❑ 
d. I am confident that I can tell whether I need to 
go to the doctor or whether I can take care of a 
health problem myself. 
❑ ❑ ❑ ❑ ❑ 
e. I am confident that I can tell a doctor concerns I 
have even when he or she does not ask. 
❑ ❑ ❑ ❑ ❑ 
f. I am confident that I can tell a nurse 
practitioner, and/or physician assistant 
concerns I have even when he or she does not 
ask. 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
g. I am confident that I can follow through on 
medical treatments I may need to do at home 
❑ ❑ ❑ ❑ ❑ 
h. I have been able to maintain (keep up with) 
lifestyle changes, like eating right or exercising 
❑ ❑ ❑ ❑ ❑ 
i. I know how to prevent problems with my health ❑ ❑ ❑ ❑ ❑ 
j. I am confident I can figure out solutions when 
new problems arise with my health. 
❑ ❑ ❑ ❑ ❑ 
k. I am confident that I can maintain lifestyle 
changes, like eating right and exercising, even 
during times of stress. 
❑ ❑ ❑ ❑ ❑ 
 
(PN: Use wording “are you receiving“ if answer to Q3 “In active treatment”. Use wording “did you last 
receive “if answer to Q3 “Completed treatment”.) 
(PN: Force a single response.) 
8. At what kind of medical facility (are you receiving / did you last receive) your cancer treatment? 
 
❑ Academic Medical Center/ Comprehensive Cancer Center 
❑ Community Cancer Center 
❑ Community hospital 
❑ Private physician practice 
❑ VA Medical Center 
❑ Don’t know/ I’m not sure 
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(PN: Skip Q9 if answer to Q3 “Diagnosed and have a plan for treatment but not yet begun treatment”.) 
(PN: Force one response but allow multiple responses.) 
9. What type of cancer treatment have you received? Please select all that apply. 
 
❑ Surgery 
❑ Radiation 
❑ Interventional Radiology 
❑ Intravenous (I.V.) Chemotherapy 
❑ Oral (pill) Chemotherapy 
❑ Oral (pill) Hormonal Therapy 
❑ Treatment targeted specifically for (PN: Pipe in Q6 answer.) cancer 
❑ Immunotherapy 
❑ Complementary or alternative therapies 
❑ Don’t know/ I’m not sure (PN: Exclusive answer.) 
 
 
(PN: Skip Q10 if answer to Q3 “Diagnosed and have a plan for treatment but not yet begun treatment”.) 
(PN: Force one response.) 
10. What was your employment status while you were being treated for cancer? 
 
❑ I continued working full time 
❑ I continued working part time 
❑ I switched from working full time to working part time 
❑ I stopped working 
❑ Does not apply, I was not working before receiving treatment 
 
 
The next set of questions is about your insurance coverage for your cancer care. 
 
 
(PN: Force a single response.) 
11. Overall, how well do you think you understand what your insurance covers for your cancer care? 
 
Do Not 
Understand At All 
Understand 
Slightly 
Understand 
Somewhat 
Understand 
Very Well 
Understand 
Completely 
❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Force a single response.) 
12. Overall, how difficult or easy is it for you to understand what your insurance covers for your cancer 
care? 
 
Very 
Difficult 
 
Somewhat 
Difficult 
Neither 
Difficult nor 
Easy 
 
Somewhat 
Easy 
 
Very 
Easy 
❑ ❑ ❑ ❑ ❑ 
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(PN: Force a single response.) 
13. Overall, how satisfied are you with your insurance coverage for your cancer treatment? 
 
Very 
Dissatisfied 
Moderately 
Dissatisfied 
Neither Satisfied 
nor Dissatisfied 
Moderately 
Satisfied 
Very 
Satisfied 
❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Randomize list.) 
(PN: Force a single response for each statement.) 
14. How satisfied are you with the following aspects of your insurance coverage for your cancer 
treatment? 
 
 
  
Very 
Dissatisfied 
 
Somewhat 
Dissatisfied 
Neither 
Satisfied nor 
Dissatisfied 
 
Somewhat 
Satisfied 
 
Very 
Satisfied 
 
No 
Opinion 
a. The choice of doctors ❑ ❑ ❑ ❑ ❑ ❑ 
b. The choice of hospitals and/or 
treatment centers 
❑ ❑ ❑ ❑ ❑ ❑ 
c. Affordability of co-payments ❑ ❑ ❑ ❑ ❑ ❑ 
d. Affordability of deductibles ❑ ❑ ❑ ❑ ❑ ❑ 
e. My ability to pay for 
medications recommended by 
my doctor 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
f. Amount I have to pay for the 
tests recommended by my 
doctor 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
g. In-network access to 
psychological 
counseling/support 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
h. Access to an insurance case 
manager who explains/assists 
with coverage issues 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
i. Access to Clinical trials ❑ ❑ ❑ ❑ ❑ ❑ 
j. Access to newly approved 
treatments or drugs 
❑ ❑ ❑ ❑ ❑ ❑ 
k. Access to advanced imaging 
technology 
❑ ❑ ❑ ❑ ❑ ❑ 
l. Access to complementary 
therapies such as acupuncture 
or massage 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
m. Getting timely approvals for 
tests or procedures 
❑ ❑ ❑ ❑ ❑ ❑ 
n. Access to genetic testing ❑ ❑ ❑ ❑ ❑ ❑ 
 
 
 
(PN: Force a single response.) 
 
15. Are you concerned you may lose your insurance if you are unable to work? 
 
❑ Yes 
❑ No 
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(PN: Force a single response.) 
16. Do you have access to alternative health insurance coverage if you are unable to work and lose your 
employer sponsored coverage? 
 
❑ Yes 
❑ No 
❑ Don’t know 
 
(PN: Force a single response.) 
17. Overall, how difficult or easy was it to find a doctor to treat you for cancer who takes your 
insurance? 
 
Very 
Difficult 
 
Somewhat 
Difficult 
Neither 
Difficult or 
Easy 
 
Somewhat 
Easy 
 
Very 
Easy 
❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Force a single response.) 
18. If your insurance had no limits, would you have chosen a different doctor? 
 
❑ Yes 
❑ No 
❑ I’m not sure 
 
 
(PN: Force a single response.) 
19. Overall, how difficult or easy was it to find a really good hospital or cancer treatment center that takes 
your insurance? 
 
Very 
Difficult 
 
Somewhat 
Difficult 
Neither 
Difficult nor 
Easy 
 
Somewhat 
Easy 
 
Very 
Easy 
❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Force a single response.) 
20. If your insurance had no limits, would you have chosen a different hospital or treatment center? 
 
❑   Yes 
❑ No 
❑ I’m not sure 
 
 
(PN: Force a single response.) 
21. If your insurance had no limits, would you have chosen to get different cancer treatment than you are 
receiving/received? 
 
❑ Yes 
❑ No 
❑ I’m not sure 
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(PN: Force a single response.) 
22. Have you heard of cancer treatment plans that are limited or required by an insurance company? 
 
❑ Yes 
❑ No 
❑ I’m not sure 
 
 
The next set of questions is about the financial issues related to your overall experience being treated for 
cancer. 
 
 
(PN: Force a single response.) 
23. Thinking about the time when you were getting cancer treatment, how distressed (e.g. anxious, 
extremely upset, or in emotional pain) were you from worrying thinking about your finances? 
 
❑ Not at all distressed 
❑ A little distressed 
❑ Somewhat distressed 
❑ Very distressed 
❑ Extremely distressed 
 
 
(PN: Force a single response.) 
24. To what degree has your cancer treatment caused you financial hardship (ie. you are/were unable to 
meet your financial obligations because of your cancer treatment trouble paying your bills)? 
 
 
None 
 
A little 
 
Some 
 
A lot 
An extreme 
amount 
❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Randomize list.) 
(PN: Force a single response for each statement.) 
25. How often do you do each of the following in order to REDUCE your expenses related to your cancer 
treatment? 
 
  
Never 
 
Rarely 
 
Sometimes 
 
Often 
 
Always 
 
N/A 
a. Postpone or skip doctor's 
appointments 
❑ ❑ ❑ ❑ ❑ ❑ 
b. Postpone or skip follow-up 
testing ❑ ❑ ❑ ❑ ❑ ❑ 
c. Postpone or skip blood work ❑ ❑ ❑ ❑ ❑ ❑ 
d. Postpone or not fill prescriptions ❑ ❑ ❑ ❑ ❑ ❑ 
e. Delay or skip complementary 
treatment (such as 
acupuncture, massage therapy, 
nutrition counseling) 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
f. Postpone or skip psychological 
counseling or support ❑ ❑ ❑ ❑ ❑ ❑ 
g. Skip dosages of prescribed 
drugs 
❑ ❑ ❑ ❑ ❑ ❑ 
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h. Cut pills in half ❑ ❑ ❑ ❑ ❑ ❑ 
i. Apply for co-pay assistance to 
cover medication costs 
❑ ❑ ❑ ❑ ❑ ❑ 
j. Discuss changing my treatment 
to one that costs less ❑ ❑ ❑ ❑ ❑ ❑ 
k. Choose to use a lower cost 
medication than what the doctor 
recommended 
❑ ❑ ❑ ❑ ❑ ❑ 
l. Apply for financial assistance 
for non-medical expenses such 
as transportation 
❑ ❑ ❑ ❑ ❑ ❑ 
m. Order medications on-line from 
non-US sources 
❑ ❑ ❑ ❑ ❑ ❑ 
n. Apply for financial assistance 
from my doctor/hospital ❑ ❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Force a single response but allow multiple responses.) 
26. Who have you spoken to in your doctor’s office about treatment costs? Please select all that apply. 
 
❑    Primary Care Physician 
❑ Doctor treating me for cancer 
❑ Physician Assistant or Nurse Practitioner 
❑ Nurse 
❑ Physician office staff member (e.g. receptionist, office manager) 
❑ Patient Financial Services staff member 
❑ Social Worker 
❑ No one 
❑ Other    
 
 
(PN: Repeat Q27 for each person selected in Q26.) 
(PN: Force a single response.) 
27. When did you first discuss treatment costs of with the (PN: With each repeat of Q27 pipe in the 
respective name of person selected in Q26.)? 
 
❑ While scheduling my first appointment 
❑ When first discussing treatment options with the doctor 
❑ After learning what my insurance would cover but before starting treatment 
❑ After starting treatment 
❑ When I realized that paying the bills was becoming a problem 
❑ Other    
 
 
(PN: Force a single response but allow multiple responses.) 
28. Who in your doctor’s office offered you help or advice about paying your medical bills? Please select 
all that apply: 
❑ Primary Care Physician 
❑ Doctor treating me for cancer 
❑ Patient Financial Services staff member 
❑ Physician Assistant or Nurse Practitioner 
❑ Nurse 
❑ Physician office staff member (e.g. receptionist, office manager) 
❑ Social Worker 
❑ No one 
❑ Other    
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(PN: Ask Q29 for each Q28 selected.) 
(PN: Force a single response for each person.) 
29. How helpful was the advice about paying your medical bills that you received from each of the 
following? 
 
 Very 
Unhelpful 
Somewhat 
Unhelpful 
Neither Helpful 
nor Unhelpful 
Somewhat 
Helpful 
 
Very Helpful 
Primary Care Physician ❑ ❑ ❑ ❑ ❑ 
Doctor treating me for cancer ❑ ❑ ❑ ❑ ❑ 
Physician Assistant or Nurse 
Practitioner 
❑ ❑ ❑ ❑ ❑ 
Nurse ❑ ❑ ❑ ❑ ❑ 
Physician office staff member (e.g. 
receptionist, office manager) 
❑ ❑ ❑ ❑ ❑ 
Patient Financial advisor ❑ ❑ ❑ ❑ ❑ 
Other ❑ ❑ ❑ ❑ ❑ 
Social Worker ❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Ask Q30 if ALL answers to Q29 were “Very Unhelpful” or “Somewhat Unhelpful”.) 
(PN: Force a single response.) 
30. Overall, have you gotten the help you need to manage your medical bills? 
 
❑ Yes 
❑ No 
❑ Not sure yet 
 
 
(PN: Force a single response.) 
31. How often do you feel your healthcare team takes your financial situation into consideration when 
recommending treatment options? 
 
Never Rarely Sometimes Often Always 
❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Force a single response.) 
32. Which of the following BEST describes how often you discuss your financial concerns with 
someone in your doctor’s office? 
 
❑ Every appointment 
❑ Whenever I get a bill 
❑ Monthly 
❑ Every few months 
❑ Rarely 
❑ Never 
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(PN: Randomize list.) 
(PN: Force a single response but allow multiple responses.) 
33. Which of the following have you experienced as a result of bills related to your cancer treatment? Please 
select all that apply: 
 
❑ I asked for financial help from a church or community organization 
❑ I applied for financial assistance from a patient support organization 
❑ I considered declaring bankruptcy 
❑ I declared bankruptcy 
❑ I borrowed money from a bank or credit union 
❑ I cut back on non-essential expenses, such as vacations, movies, dining out 
❑ I borrowed money from family/friends 
❑ I moved to a less expensive home 
❑ I missed rent/mortgage payments 
❑ I cut back on groceries, transportation, clothing, tuition 
❑ I missed paying bills such as heat, electricity, phone 
❑ I applied for financial assistance from my doctor’s office or hospital 
❑ Other (please specify)     
 
 
(PN: Force a single response.) 
34. Have you considered cashing in your life insurance to pay for your cancer treatment? 
 
❑ Yes 
❑ No 
❑ Not applicable, I don’t have life insurance 
 
 
(PN: Force a single response.) 
35. Have you taken money from your pension plan or retirement account to pay for your cancer 
treatment? 
❑ Yes 
❑ No 
❑ Not applicable, I don’t have a pension plan or retirement account 
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(PN: Randomize list.) 
(PN: Force a single response for each statement.) 
36. Thinking about your experience being treated for cancer, how often do you (or did you) do the 
following? 
 
  
Never 
 
Rarely 
 
Sometimes 
 
Often 
 
Always 
a. Determine the expense to you before 
going to the emergency room 
❑ ❑ ❑ ❑ ❑ 
b. Estimate the cost to you before agreeing 
to a treatment your doctor recommended 
❑ ❑ ❑ ❑ ❑ 
c. Appeal the denial of benefits from your 
insurance company 
❑ ❑ ❑ ❑ ❑ 
d. Find out the cost to you before filling a 
prescription for a treatment drug 
❑ ❑ ❑ ❑ ❑ 
e. Find out the cost to you before filling a 
prescription for a drug that helps with 
side effects or symptoms 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
f. Review the explanation of benefits from 
your insurance company 
❑ ❑ ❑ ❑ ❑ 
g. Ask the insurance company for help in 
understanding your coverage 
❑ ❑ ❑ ❑ ❑ 
h. Consider changing to a different doctor 
because of cost 
❑ ❑ ❑ ❑ ❑ 
i. Find out the cost to you before getting 
lab tests or scans 
❑ ❑ ❑ ❑ ❑ 
j. Agree to a test or procedure that your 
insurance didn’t cover 
❑ ❑ ❑ ❑ ❑ 
k. Consider non-traditional treatment that 
costs less 
❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Show following definition on same page as each of next 3 questions.) 
 
 
(PN: Force a single response.) 
37. Are you familiar with term “formulary” as described above? 
 
❑ Yes 
❑ No 
 
 
(PN: Force a single response.) 
38. Are you aware that insurance plans often have several levels of coverage for cancer drugs and that the 
amount you pay out of pocket may change depending on the drugs your doctor prescribes? 
 
❑ Yes 
❑ No 
❑ I’m not sure 
 
A “formulary” is a list of drugs that your insurer covers. There are often several levels (or tiers) 
within the formulary and the amount of coverage for a drug varies depending on the level it is in. 
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(PN: Force a single response.) 
39. Are you aware that your co-pay amount may be different depending on if you are receiving 
treatment in the hospital or in your doctor’s office? 
 
❑ Yes 
❑ No 
❑ I’m not sure 
 
 
(PN: Only ask Q40 if answer to Q4 was “Medicare/Medicaid” or “Private Medigap” AND answer to Q9 
was “Intravenous Chemotherapy (I.V.)”.) 
40. Was your infusion (ie. intravenous or I.V.) therapy covered under Medicare Part B (your medical 
benefits)? 
 
❑ Yes 
❑ No 
❑ I’m not sure 
 
 
(PN: Only ask Q41 if answer to Q40 was “Yes”.) 
41. On average, what was the co-pay per infusion? 
 
❑ Less than $50 
❑ $51 - $150 
❑ $151 - $300 
❑ $301 - $500 
❑ More than $500 
 
 
(PN: Only ask Q42 if answer to Q4 was “Medicare/Medicaid” or “Private Medigap” AND answer to Q9 
was “Oral Chemotherapy (Pill)” or “Oral Hormonal Therapy (Pill)”.) 
42. Was your oral therapy covered under Medicare Part D (your drug benefits)? 
 
❑ Yes 
❑ No 
❑ I’m not sure 
 
 
(PN: Only ask Q43 if answer to Q42 was “Yes”.) 
43. On average, what was the co-pay per prescription? 
 
❑ Less than $50 
❑ $51 - $150 
❑    $151 - $300 
❑    $301 - $500 
❑ More than $500 
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(PN: Randomize list.) 
(PN: Force a single response for each statement.) 
44. How difficult or easy was it for you to determine the out-of pocket cost of each of the following 
BEFORE you incurred the expense? 
 
  
Very 
Difficult 
 
Somewhat 
Difficult 
 
Neither 
Difficult nor Easy 
 
Somewhat 
Easy 
 
Very 
Easy 
 
Not 
Applicable 
a. Scans and X-rays ❑ ❑ ❑ ❑ ❑ ❑ 
b. Procedures ❑ ❑ ❑ ❑ ❑ ❑ 
c. Treatments ❑ ❑ ❑ ❑ ❑ ❑ 
d. Physician fees ❑ ❑ ❑ ❑ ❑ ❑ 
e. Hospital fees ❑ ❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Randomize list.) 
(PN: Force a single response for each statement.) 
45. Thinking about the time you were getting cancer treatment, on average, how much did you spend out 
of pocket each month on the following? Your best estimate will do. 
 
 Less than 
$100 
 
$101-250 
 
$251-500 
More than 
$500 
Don’t know/ 
I’m not sure 
a. Co-payments and deductibles 
for drugs, doctor visits and tests 
❑ ❑ ❑ ❑ ❑ 
b. Non-prescription medications 
(that is, over-the-counter drugs) 
❑ ❑ ❑ ❑ ❑ 
c. Services to help with symptoms 
and side effects such as 
acupuncture or massage 
therapy 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
 
❑ 
d. Transportation to and from 
clinic visits, baby-sitting, 
❑ ❑ ❑ ❑ ❑ 
e. Special clothing, wigs, etc. ❑ ❑ ❑ ❑ ❑ 
 
 
(PN: Force response) 
46. What percent of your total cancer treatment costs do you think have been covered by your 
insurance? Your best estimate will do. 
 
    % of total treatment costs covered by insurance 
 
❑ I’m not sure 
 
 
The remaining few questions are asked to provide us with some demographic information so we can 
better understand the study findings. 
 
 
(PN: Force a single response.) 
47. What is your gender? 
 
❑ Male 
❑ Female 
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(PN: Force a single response.) 
48. What Is Your Ethnicity? 
 
❑ African American 
❑ Asian 
❑ Hispanic 
❑ Pacific Islander 
❑ White (not Hispanic) 
❑ Multi-racial 
❑ Other 
 
 
(PN: Force a single response.) 
49. What was your total 2014 household income before taxes? 
 
❑ Less than $25,000 
❑    $25,000 to $34,999 
❑    $35,000 to $49,999 
❑    $50,000 to $74,999 
❑    $75,000 to $99,999 
❑ $100,000 to $149,999 
❑ $150,000 or more 
❑ Prefer not to answer 
 
(PN: Force a single response.) 
50. What is the highest level of education or degree you have completed? 
 
❑ Less than high school 
❑ High school graduate (includes equivalency) 
❑ Some college, no degree 
❑ Associate's degree 
❑ Bachelor's degree 
❑ Master’s degree 
❑ Doctorate / professional degree 
 
 
(PN: Allow multiple responses.) 
51. If you have Commercial/Private insurance, who is your provider? Please select all that apply. 
 
❑ Private insurance through an employer 
❑ United Healthcare 
❑   Aetna 
❑   Cigna 
❑ Humana 
❑ Kaiser Permanente 
❑ Blue Cross Blue Shield 
❑ Other (please specify) 
 
This completes the survey. Thank you very much for your feedback. 
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Appendix 2. Signed Data Use Agreement 
 
Data Use Agreement: CancerCare Data Set 
All individuals with access to the data are to sign and submit along with a CancerCare Manuscript Proposal  
 
Investigator Name: Meredith Doherty 
Investigator Institution: 
Project Title: 
Lead Data Manager: 
 
CancerCare Data Set will be released to the above referenced investigator, as indicated here. Methodology and 
survey demographics are attached: 
 
(a) Patient Survey 1: Understanding the Diagnosis of Cancer 
(b) Patient Survey 2: Participation in Treatment Planning and Decisions 
(c) Patient Survey 3: Communication with the Care Team 
(d) Patient Survey 4: Financial and Insurance Issues 
(e) Patient Survey 5: Symptoms, Side Effects and Quality of Life 
(f) Patient Survey 6: Survivorship 
 
In accepting this data from CancerCare, the Investigator agrees to use the data only for the CancerCare approved 
research project. (Attach Manuscript Proposal) 
 
Investigator agrees to submit a new proposal to CancerCare for any new project in which the data is to be used and 
will not proceed to use the data for an additional project with_out approval and a signed agreement from 
CancerCare. 
 
The data may only be shared within the_ team w d cting the analysis pr ject. Requests from other individuals for 
access to the data should be referred to the CancerCare Data Set Manager (Ellen Sonet). 
 
The investigator agrees to follow the CancerCare Data Set Policies on Data Management and Security as follows: 
 
1. Use or disclose the data set only as permitted by this Agreement or as required by law; 
2. Use appropriate safeguards to prevent use or disclosure of the DATA SET other than as permitted by this 
Agreement or required by law; 
3. Report to CancerCare any use or disclosure of the data set of which it becomes aware that is not permitted by this 
Agreement or required by law, including the presence of prohibited identifiers in the data set; 
4. Require any of Investigators' subcontractors or,agents that receive or have access to the data set to agree to the same 
restrictions and conditions on the use and/or disclosure of the data set that apply to Investigator under this 
Agreement; and 
5. Not use the information in the data set, alone or in combination, to identify or contact the individuals who are 
data subjects. 
 
The term of this Agreement begins as of the effective date and terminates 5 years from effective date. If the 
Investigator desires to keep the data set for a longer period, a justification in writing should be made to 
CancerCare. 
 
Investigator may terminate this agreement at any time by notifying CancerCare and returning or destroying the data 
set. 
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CancerCare will provide written notice to Investigator withi  ten _(1_0).days. of  any determination  that  he/she  has 
breached a material term of this Agreement. CancerCare shall afford Investigator an opportunity  to  cure said  alleged 
material breach upon mutually agreeable terms. Failure to agree on mutually agreeable terms  for  cure within thirty 
{30) days shall be grounds for the immediate termination of this Agreement by CancerCare. 
 
 
Ellen Sonet will serve as the lead data manager for this analytic project and will serve as the liaison with the 
CancerCare.
All CancerCare Data Set publications must be prepared in collaboration with CancerCare and co-authored by a 
CancerCare staff member. Any exceptions to this requirement must be noted and agreed to as part 
of this agreement. 
 
Exception: Meredith Doherty may access this data for her dissertation and derivative 
publications, which are exempt from CancerCare co-author requirements. 
 
Copies of all manuscripts arising from the project must be sent to the CancerCare prior to 
publication, for reference. 
 
Any publication using CancerCare Data Set data must acknowledge the contributions of the 
CancerCare Data Set to the project with the following citation: "This publication was supported by 
CancerCare and is based on data from its :20_1_6 Patient Access and Engagement Study." 
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Effective Date: 2//( /]    
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Appendix 3. IRB Determination Notice 
 
 
University Integrated Institutional Review Board
205 East 42
nd
 Street
New York, NY 10017
 http://www.cuny.edu/research/compliance.html
Determination Notice
Activity Does Not Require CUNY HRPP/IRB Review
06/28/2017
Meredith Doherty,
Hunter College
RE: IRB File #2017-0067
Exploring Themes of Patient Access and Engagement in Cancer Care: Financial Wellbeing,
Quality of Life and Value.
Dear Meredith Doherty,
The above-referenced research proposal was reviewed on 06/28/2017. Based on the information you
have provided, the proposed research does not require CUNY HRPP or IRB review because:
[ ] It does not meet the CUNY HRPP definition of  research: A systematic investigation,
 including research development, testing and evaluation, designed to develop or contribute to
 generalizable knowledge.                       
[X] It does not involve  human subjects as defined by CUNY HRPP: A living individual about
 whom an investigator (whether professional or student) conducting research obtains (1) data
 through intervention or interaction with the individual, or (2) identifiable private information.
[ ] CUNY is not engaged in the proposed research: CUNY employees or agents1 obtain, for
 the purposes of the research project, (1) data about the subjects of the research through
 intervention or interaction with them; (2) identifiable private information about the subjects of
 the research; or (3) the informed consent of human subjects for the research.
Comments:
Please refer to CUNY HRPP Guidance: When is CUNY HRPP or IRB Review Required  for further
 clarification regarding these criteria. Should your proposed activity change, please re-submit to
 the CUNY HRPP for re-evaluation of this determination.
1
Employees or agents refers to individuals who: (1) act on behalf of CUNY; (2) exercise institutional authority or responsibility; or (3) perform
institutionally designated activities. Employees or agents can include staff, students, contractors, and volunteers, among others, regardless of whether
the individual is receiving compensation.
If you have any questions, please contact:
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